

**CÔNG TY CỔ PHẦN
DƯỢC VẬT TƯ Y TẾ HẢI DƯƠNG
HAI DUONG PHARMACEUTICAL
MEDICAL MATERIALS JSC.**

Số: ~~44~~/2026/NQ-ĐHĐCĐ-DHD
No:/2026/NQ-ĐHĐCĐ-DHD

**CỘNG HÒA XÃ HỘI CHỦ NGHĨA VIỆT NAM
SOCIALIST REPUBLIC OF VIETNAM**

**Độc lập – Tự do – Hạnh phúc
Independence – Liberty – Happiness**
Hải Phòng, ngày 07 tháng 4 năm 2026
Hai Phong, April 07, 2026

**NGHỊ QUYẾT
ĐẠI HỘI ĐỒNG CỔ ĐÔNG THƯỜNG NIÊN NĂM 2026
CÔNG TY CỔ PHẦN DƯỢC VẬT TƯ Y TẾ HẢI DƯƠNG
RESOLUTION
2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS
HAI DUONG PHARMACEUTICAL MEDICAL MATERIALS JOINT STOCK COMPANY**

Căn cứ / In accordance with:

- Luật Doanh nghiệp số 59/2020/QH14 ngày 17/6/2020 đã được Quốc hội Nước Cộng Hòa Xã hội Chủ Nghĩa Việt Nam thông qua, sửa đổi bởi Luật số 03/2022/QH15 được Quốc hội thông qua ngày 11/01/2022 và Luật số 76/2025/QH15 được Quốc hội thông qua ngày 17/06/2025 và các văn bản hướng dẫn thi hành;
- *The Law on Enterprises No. 59/2020/QH14 dated June 17, 2020, passed by the National Assembly of the Socialist Republic of Vietnam, amended by Law No. 03/2022/QH15, passed by the National Assembly of the Socialist Republic of Vietnam on January 11, 2022, and Law No. 76/2025/QH15, passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2025, and its implementing guidance documents;*
- Điều lệ tổ chức và hoạt động của Công ty Cổ phần Dược Vật tư Y tế Hải Dương;
Charter on organization and operation of Hai Duong Pharmaceutical Medical Materials Joint Stock Company;
- Biên bản họp Đại hội đồng cổ đông thường niên năm 2026 số 43/2026/BB-ĐHĐCĐ-DHD ngày 07/04/2026 của Công ty Cổ phần Dược Vật tư Y tế Hải Dương.
Minutes of the 2026 Annual General Meeting of Shareholders No. 43/2026/BB-ĐHĐCĐ-DHD dated April 7, 2026 of Hai Duong Pharmaceutical Medical Materials Joint Stock Company.

**QUYẾT NGHỊ:
RESOLUTION**

Điều 1. Thông qua các Báo cáo trình Đại hội theo Tờ trình số 01/Ttr-HĐQT của Hội đồng quản trị, cụ thể như sau:

Article 1. *Approval of the Reports submitted to the Congress according to Proposal No. 01/Ttr-HĐQT of the Board of Directors, specifically as follows:*

- Báo cáo hoạt động của Hội đồng quản trị năm 2025;



- Report on the activities of the Board of Directors in 2025;*
- Báo cáo hoạt động của Ban kiểm soát năm 2025;
Report on the activities of the Board of Supervisors in 2025;
 - Báo cáo hoạt động sản xuất kinh doanh năm 2025 và kế hoạch năm 2026.
Report on production and business activities in 2025 and plan for 2026.

Điều 2. Thông qua Báo cáo tài chính năm 2025 đã được kiểm toán theo Tờ trình số 02/Ttr-HĐQT của Hội đồng quản trị.

Article 2. Approval of the audited 2025 Financial Report according to Proposal No. 02/Ttr-HDQT of the Board of Directors.

Điều 3. Thông qua Phương án phân phối lợi nhuận năm 2025 và dự toán tài chính năm 2026 theo Tờ trình số 03/Ttr-HĐQT của Hội đồng quản trị.

Article 3. Approve the 2025 profit distribution plan and 2026 financial budget according to Proposal No. 03/Ttr-HDQT of the Board of Directors.

Điều 4. Thông qua việc chi trả thù lao cho HĐQT, BKS năm 2025 và đề xuất năm 2026 theo Tờ trình số 04/Ttr-HĐQT của Hội đồng quản trị.

Article 4. Approval of remuneration payment for the Board of Directors and the Board of Supervisors in 2025 and the proposal for 2026 according to Proposal No. 04/Ttr-HDQT of the Board of Directors.

Điều 5. Thông qua việc lựa chọn đơn vị kiểm toán BCTC năm 2026 theo Tờ trình số 05/Ttr-HĐQT của Hội đồng quản trị

Article 5. Approval of the selection of the 2026 Financial Statements Auditing Unit according to Proposal No. 05/Ttr-HDQT of the Board of Directors

Điều 6. Thông qua phương án phát hành cổ phiếu để tăng vốn cổ phần từ nguồn vốn chủ sở hữu năm 2026 theo Tờ trình số 06/Ttr-HĐQT của Hội đồng quản trị.

Article 6. Approval of the plan for Issuing Shares to Increase Charter Capital from Owner's Equity in 2026 according to Proposal No. 06/Ttr-HDQT of the Board of Directors.

Điều 7. Thông qua sửa đổi, bổ sung Ngành nghề kinh doanh của Công ty theo Tờ trình số 07/Ttr-HĐQT của Hội đồng quản trị.

Article 7: Approval of Amendments, supplements to the Business Line of the Company according to Proposal No. 07/Ttr-HDQT of the Board of Directors.

Điều 8. Thông qua thay đổi Điều lệ tổ chức và hoạt động của Công ty theo Tờ trình số 08/Ttr-HĐQT của Hội đồng quản trị.

Article 8: Approval of Amendments to the Company's Charter on the organization and operation according to Proposal No. 08/Ttr-HDQT of the Board of Directors.

Điều 9. Thông qua các hợp đồng, giao dịch giữa Công ty Cổ phần Dược Vật tư Y tế Hải Dương với người có liên quan theo Tờ trình số 09/Ttr-HĐQT của Hội đồng quản trị.

Article 9: Approves the contracts, transactions between Hai Duong Pharmaceutical Medical Materials JSC and the related persons according to Proposal No. 09/Ttr-HDQT of the Board of



Directors.

Nghị quyết được ĐHĐCĐ thường niên năm 2026 của Công ty Cổ phần Dược Vật tư Y tế Hải Dương thông qua toàn văn ngay tại cuộc họp. Hội đồng quản trị, Ban kiểm soát, Ban Giám đốc và các phòng ban liên quan có trách nhiệm thi hành nghị quyết này.

The Resolution was approved in full by the 2026 Annual General Meeting of Shareholders of Hai Duong Pharmaceutical Medical Materials Joint Stock Company. The Board of Directors, the Board of Supervisors, the Board of Management and relevant departments are responsible for implementing this Resolution.

Nghị quyết này có hiệu lực kể từ ngày ký./.

This Resolution takes effect from the date of signing./.

Nơi nhận / Recipients:

- Quý cổ đông;
Shareholders
- HĐQT, BKS, BGĐ, Thư ký Công ty;
Board of Directors, Supervisors, Management
and Company Secretary
- Lưu VT.
Archives

TM. ĐẠI HỘI ĐỒNG CỔ ĐÔNG NĂM 2026

CHỦ TỌA ĐẠI HỘI

**ON BEHALF OF THE 2026 GENERAL
MEETING**

CHAIRMAN



NGUYỄN TRUNG VIỆT



**CÔNG TY CỔ PHẦN
DƯỢC VẬT TƯ Y TẾ HẢI DƯƠNG
HAI DUONG PHARMACEUTICAL
MEDICAL MATERIALS JSC.**

Số: 45/2026/BB-ĐHĐCĐ-DHD

No:/2026/BB-ĐHĐCĐ-DHD

**CỘNG HÒA XÃ HỘI CHỦ NGHĨA VIỆT NAM
SOCIALIST REPUBLIC OF VIETNAM**

**Độc lập – Tự do – Hạnh phúc
Independence – Liberty – Happiness**

Hải Phòng, ngày 07 tháng 04 năm 2026

Hai Phong, April 07, 2026

BIÊN BẢN HỌP

**ĐẠI HỘI ĐỒNG CỔ ĐÔNG THƯỜNG NIÊN NĂM 2026
CÔNG TY CỔ PHẦN DƯỢC VẬT TƯ Y TẾ HẢI DƯƠNG**

MEETING MINUTES

2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS

HAI DUONG PHARMACEUTICAL MEDICAL MATERIALS JOINT STOCK COMPANY

Tên doanh nghiệp <i>Business Name</i>	: Công ty Cổ phần Dược Vật tư Y tế Hải Dương Hai Duong Pharmaceutical Medical Materials Joint Stock Company
Địa chỉ trụ sở chính <i>Head Office Address</i>	: Số 102 Chi Lăng, phường Thành Đông, thành phố Hải Phòng <i>No. 102 Chi Lang, Thanh Dong ward, Hai Phong city</i>
Giấy chứng nhận đăng ký doanh nghiệp <i>Enterprise Registration Certificate</i>	: Số 0800011018 do Sở Kế hoạch và Đầu tư tỉnh Hải Dương cấp lần đầu ngày 04/04/2003, cấp thay đổi lần thứ 23 ngày 16/7/2025 <i>Number 0800011018, first issued by the Department of Planning and Investment of Hai Duong province on April 4, 2003, with the 23st amendment issued on July 16, 2025.</i>
Thời gian họp <i>Meeting time</i>	: Bắt đầu lúc 08 giờ 00 phút, ngày 07/04/2026 <i>Starts at 08:00, April 7, 2026</i>
Địa điểm họp <i>Meeting venue</i>	: Trung tâm tổ chức sự kiện Âu Cơ (số 1A, phố Nguyễn Hữu Cầu, phường Hải Dương, thành phố Hải Phòng) <i>Au Co Event Center (No. 1A, Nguyen Huu Cau Street, Hai Duong Ward, Hai Phong City)</i>
Chương trình và nội dung đại hội <i>Meeting agenda</i>	: Theo Chương trình Đại hội đồng cổ đông thường niên năm 2026 đã được Đại hội đồng cổ đông thông qua <i>According to the approved 2026 Annual General Meeting of Shareholders Agenda</i>

DIỄN BIẾN ĐẠI HỘI (theo trình tự thời gian) / MEETING PROCESS (in chronological order):

I. THỦ TỤC KHAI MẠC ĐẠI HỘI / OPENING PROCEDURES

- Ban tổ chức đã thực hiện thủ tục đăng ký dự họp cho các đại biểu tới tham dự Đại hội đồng cổ đông thường niên năm 2026 của Công ty Cổ phần Dược Vật tư Y tế Hải Dương.

The Organizing Committee completed the registration procedures for delegates to attend the 2026 Annual General Meeting of Shareholders of Hai Duong Pharmaceutical Medical

Materials Joint Stock Company.

- Đại hội đã nghe Bà Nguyễn Thị Hương Lan - Trưởng Ban kiểm tra tư cách đại biểu báo cáo kết quả thẩm tra tư cách đại biểu, cụ thể:

The Congress listened to Mrs. Nguyen Thi Huong Lan - Head of the Delegate Eligibility Examination Committee report on the results of the examination, specifically:

- Tại thời điểm khai mạc Đại hội lúc 08 giờ 00 phút, Đại hội có: **162** đại biểu dự họp, đại diện cho **31.804.278** cổ phần, chiếm **88,36%** tổng số cổ phần có quyền biểu quyết.

At the opening time of the Meeting at 08:00, there were: 162 delegates attending the meeting, representing 31,804,278 shares, accounting for 88.36% of the total number of shares with voting rights.

- Căn cứ theo Luật Doanh nghiệp 2025, Điều lệ tổ chức và hoạt động của Công ty, Đại hội đồng cổ đông thường niên năm 2026 của Công ty Cổ phần Vật tư Y tế Hải Dương khai mạc lúc 08 giờ 00 phút, ngày 07/4/2026 là hoàn toàn hợp pháp, hợp lệ và có đầy đủ điều kiện tiến hành Đại hội theo quy định.

In accordance with the Law on Enterprises 2025, the Charter of organization and operation of the Company, the 2026 Annual General Meeting of Shareholders of Hai Duong Pharmaceutical Medical Materials Joint Stock Company opening at 08:00 on April 7, 2026 is completely legal, valid and fully eligible to proceed.

II. NỘI DUNG VÀ TIẾN TRÌNH ĐẠI HỘI / CONTENT AND PROCESS OF THE MEETING

Đại hội đã tiến hành theo tiến trình như sau / *The Meeting proceeded as follows:*

1. Giới thiệu thành phần tham dự Đại hội / Introduction of participants:

Hội đồng quản trị / Board of Directors:

- | | |
|---|--|
| - Ông Nguyễn Trung Việt
<i>Mr. Nguyen Trung Viet</i> | Chủ tịch Hội đồng quản trị
<i>Chairman</i> |
| - Ông Trần Phúc Dương
<i>Mr. Tran Phuc Duong</i> | Thành viên Hội đồng quản trị
<i>Member of the board</i> |
| - Bà Nguyễn Thị Tú Anh
<i>Mrs. Nguyen Thi Tu Anh</i> | Thành viên Hội đồng quản trị
<i>Member of the board</i> |

Ban Kiểm soát / Board of Supervisors:

- Bà Phạm Thị Thùy <i>- Mrs. Pham Thi Thuy</i>	Trưởng Ban kiểm soát <i>Head of the Board of Supervisors</i>
- Ông Trần Kim Cương <i>Mr. Tran Kim Cuong</i>	Thành viên Ban kiểm soát <i>Member of the Board of Supervisors</i>
- Bà Nguyễn Thị Hương Lan <i>Mrs. Nguyen Thi Huong Lan</i>	Thành viên kiểm soát <i>Member of the Board of Supervisors</i>

Ban Điều hành / Board of Management:

- Bà Nguyễn Thị Tú Anh Tổng Giám đốc
Mrs. Nguyen Thi Tu Anh General Manager
- Ông Chu Văn Long Kế toán trưởng – Người phụ trách Quản trị Công ty.
Mr. Chu Van Long Chief Accountant – Person in charge of Corporate Governance.

2. Giới thiệu Đoàn chủ tọa, Ban thư ký và Ban kiểm phiếu/ Introduction of the Presidium, Secretariat and Vote Counting Committee

Bà Nguyễn Thị Tú Anh – Tổng Giám đốc giới thiệu danh sách Đoàn chủ tọa, Thư ký Đại hội và Ban kiểm phiếu của Đại hội:

Mrs. Nguyen Thi Tu Anh – General Manager of the Meeting introduced the list of the Presidium, Secretariat and the Vote Counting Committee:

a. Đoàn chủ tọa / Presidium:

- Ông Nguyễn Trung Việt – Chủ tịch HĐQT – Chủ tọa
Mr. Nguyen Trung Viet – Chairman of the Board of Directors – Chairman of the presidium
- Bà Nguyễn Thị Tú Anh – Tổng Giám đốc – Thành viên
Mrs. Nguyen Thi Tu Anh – General Manager – Member
- Ông Trần Phúc Dương – Thành viên HĐQT – Thành viên
Mr. Tran Phuc Duong – Member of Board of Directors – Member

b. Thư ký Đại hội / Meeting Secretary: The Presidium of the General Meeting

Để giúp việc và ghi chép các diễn biến của Đại hội, Đoàn Chủ tọa Đại hội giới thiệu Thư ký Đại hội:
To assist and record the proceedings of the Meeting, The Presidium of the General Meeting introduces the Secretary of the Meeting:

- Bà Trần Thị Dương – Phòng Tổ chức hành chính
Mrs. Tran Thi Duong – Administrative Department

c. Ban kiểm phiếu / Vote Counting Committee:

Để thực hiện công tác kiểm phiếu biểu quyết của Đại hội, Đoàn Chủ tọa Đại hội giới thiệu danh sách nhân sự của Ban kiểm phiếu như sau:

To carry out the vote counting for the Meeting, The Presidium of the General Meeting introduces the list of members of the Vote Counting Committee as follows:

- Nguyễn Thị Hương Lan – Trưởng ban
Nguyen Thi Huong Lan - Head of Committee
- Đỗ Thị Mai Tường – Thành viên
Do Thi Mai Tuong - Member
- Phạm Thị Vân – Thành viên
Pham Thi Van - Member

- Đào Thị Thanh Thúy –Thành viên
Dao Thi Thanh Thuy –Member
- Nguyễn Thị Kim Thoa – Thành viên
Nguyen Thi Kim Thoa –Member
- Bùi Thị Phương Anh –Thành viên
Bui Thi Phuong Anh –Member
- Nguyễn Thị Hương Giang –Thành viên
Nguyen Thi Huong Giang –Member
- Đặng Thị Thúy Vân –Thành viên
Dang Thi Thuy Van –Member
- Dương Kim Hương –Thành viên
Duong Kim Huong –Member
- Lê Thị Thu Hiền –Thành viên
Le Thi Thu Hien –Member

3. Chương trình họp, Quy chế tổ chức và biểu quyết, bầu cử / Meeting agenda, rules of organization, voting

a. Chương trình họp / Meeting agenda

Bà Nguyễn Thị Tú Anh – Tổng Giám đốc thay mặt Ban tổ chức Đại hội đọc Chương trình họp.

Mrs. Nguyen Thi Tu Anh - General Manager on behalf of the Organizing Committee read the meeting agenda.

Chương trình họp Đại hội đồng cổ đông thường niên năm 2026 bao gồm các nội dung sau:

The agenda of the 2026 Annual General Meeting of Shareholders includes the followings:

- Báo cáo hoạt động sản xuất kinh doanh năm 2025 và kế hoạch năm 2026;
Report on production and business activities in 2025 and plan for 2026;
- Báo cáo hoạt động của Hội đồng quản trị năm 2025;
Report on the activities of the Board of Directors in 2025;
- Báo cáo hoạt động của Ban Kiểm soát năm 2025;
Report on the activities of the Board of Supervisors in 2025;
- Tờ trình số 01/Ttr – HĐQT về việc thông qua Báo cáo hoạt động của HĐQT, BKS năm 2025; Báo cáo hoạt động SX- KD năm 2025 và kế hoạch SX – KD năm 2026;
Proposal No. 01/Ttr – HĐQT on the approval of the Board of Directors and Board of Supervisors's Operation Report in 2025; Production and Business Activity Report in 2025 and Production and Business Plan in 2026;
- Tờ trình số 02/Ttr – HĐQT về việc thông qua Báo cáo tài chính năm 2025 đã được kiểm toán;
Proposal No. 02/Ttr – HĐQT on the approval of the audited 2025 Financial Statements;
- Tờ trình số 03/Ttr – HĐQT về việc thông qua Phương án phân phối lợi nhuận năm 2025 và dự

toán tài chính năm 2026

Proposal No.03/TTr-HĐQT on The 2025 profit distribution plan and 2026 financial budget

- Tờ trình số 04/Ttr – HĐQT về việc thông qua chi trả thù lao cho HĐQT, BKS năm 2025 và đề xuất năm 2026;

Proposal No. 04/Ttr – HĐQT on approving remuneration payment for the Board of Directors and Board of Supervisors in 2025 and proposal for 2026;

- Tờ trình số 05/Ttr – HĐQT về việc thông qua việc lựa chọn đơn vị kiểm toán BCTC năm 2026;
Proposal No. 05/Ttr – HĐQT on approving the selection of an audit unit for the 2026 financial statements;

- Tờ trình số 06/Ttr – HĐQT phương án phát hành cổ phiếu để tăng vốn cổ phần từ nguồn vốn chủ sở hữu năm 2026;

Proposal No. 06/Ttr – HĐQT on plan for Issuing Shares to Increase Charter Capital from Owner's Equity in 2026;

- Tờ trình số 07/Ttr – HĐQT về việc thông qua sửa đổi, bổ sung Ngành nghề kinh doanh của Công ty;

Proposal No. 07/Ttr – HĐQT on Approval of Amendments, Supplements to the Business Line of the Company;

- Tờ trình số 08/Ttr – HĐQT về việc thông qua thay đổi Điều lệ tổ chức và hoạt động của Công ty.

Proposal No. 08/Ttr – HĐQT on Approval of Amendments to the Company's Charter on the organization and operation.

- Tờ trình số 09/Ttr – HĐQT về việc thông qua các hợp đồng, giao dịch giữa Công ty Cổ phần Dược Vật tư Y tế Hải Dương với người có liên quan.

Proposal No. 09/Ttr – HĐQT on approval of the contracts, transactions between Hai Duong Pharmaceutical Medical Materials JSC and the related persons.

b. Quy chế tổ chức và biểu quyết / Rules on organization and voting

Bà Nguyễn Thị Tú Anh – Tổng Giám đốc thay mặt Ban tổ chức Đại hội đọc Quy chế tổ chức và biểu quyết tại Đại hội đồng cổ đông thường niên năm 2026.

Mrs. Nguyen Thi Tu Anh - General Manager on behalf of the Organizing Committee of the Meeting read the rules on organization and voting at the 2026 Annual General Meeting of Shareholders.

4. Đại hội tiến hành biểu quyết thông qua Đoàn chủ tọa, Ban kiểm phiếu, Chương trình họp, Quy chế tổ chức và biểu quyết bằng hình thức giơ Thẻ biểu quyết / The Congress voted to approve the Presidium, the Vote Counting Committee, the Meeting Agenda, the Organization and Voting Rules by raising the Voting Card.

- Đại hội đã nhất trí 100% thông qua các nội dung về thành viên Đoàn chủ tọa, Ban kiểm phiếu, Chương trình họp, Quy chế tổ chức và biểu quyết.

The Congress unanimously approved 100% of the contents regarding the members of the Presidium, the Vote Counting Committee, the Meeting Agenda, the Organization and Voting Rules

Dưới sự điều hành của Đoàn chủ tọa, Đại hội đồng cổ đông thường niên năm 2026 của Công ty Cổ phần Vật tư Y tế Hải Dương tiến hành chương trình nghị sự.

Under the direction of the Presidium, the 2026 Annual General Meeting of Shareholders of Hai Duong Pharmaceutical Medical Materials Joint Stock Company proceeded with the agenda.

III. CÁC BÁO CÁO, TỜ TRÌNH TẠI ĐẠI HỘI / REPORTS AND PROPOSALS AT THE MEETING

1. Các báo cáo trình bày tại Đại hội / Reports presented at the meeting

- Bà Nguyễn Thị Tú Anh – Tổng Giám đốc trình bày Báo cáo hoạt động sản xuất kinh doanh năm 2025 và kế hoạch năm 2026.

Mrs. Nguyen Thi Tu Anh - General Manager presented the 2025 production and business activities report and the 2026 plan.

- Ông Nguyễn Trung Việt – Chủ tịch HĐQT trình bày Báo cáo hoạt động của Hội đồng quản trị năm 2025.

Mr. Nguyen Trung Viet - Chairman of the Board of Directors presented the Board of Directors' 2025 Operation Report.

- Bà Phạm Thị Thủy –Đại diện Ban kiểm soát trình bày Báo cáo hoạt động của Ban kiểm soát năm 2025.

Mrs. Phạm Thị Thủy - Representative of the Board of Supervisors presented the Board of Supervisors' 2025 Operation Report.

2. Các tờ trình trình bày tại Đại hội / Proposals presented at the meeting

Đại hội đã nghe Đoàn chủ tọa lần lượt trình bày các tờ trình.

The Congress listened to the Presidium present the following reports:

- Tờ trình số 01/Ttr – HĐQT về việc thông qua Báo cáo hoạt động của HĐQT, BKS năm 2025; Báo cáo hoạt động SX- KD năm 2025 và kế hoạch SX – KD năm 2026;

Proposal No. 01/Ttr – HĐQT on the approval of the Board of Directors and Board of Supervisors's Operation Report in 2025; Production and Business Activity Report in 2025 and Production and Business Plan in 2026;

- Tờ trình số 02/Ttr – HĐQT về việc thông qua Báo cáo tài chính năm 2025 đã được kiểm toán;

Proposal No. 02/Ttr – HĐQT on the approval of the audited 2025 Financial Statements;

- Tờ trình số 03/Ttr – HĐQT về việc thông qua Phương án phân phối lợi nhuận năm 2025 và dự toán tài chính năm 2026

Proposal No.03/Ttr-HĐQT on The 2025 profit distribution plan and 2026 financial budget

- Tờ trình số 04/Ttr – HĐQT về việc thông qua chi trả thù lao cho HĐQT, BKS năm 2025 và đề xuất năm 2026;

Proposal No. 04/Ttr – HĐQT on approving remuneration payment for the Board of Directors and Board of Supervisors in 2025 and proposal for 2026;

- Tờ trình số 05/Ttr – HĐQT về việc thông qua việc lựa chọn đơn vị kiểm toán BCTC năm 2026;

Proposal No. 05/Ttr – HĐQT on approving the selection of an audit unit for the 2026 financial

statements;

- Tờ trình số 06/Ttr – HĐQT phương án phát hành cổ phiếu để tăng vốn cổ phần từ nguồn vốn chủ sở hữu năm 2026;

Proposal No. 06/Ttr – HĐQT on plan for Issuing Shares to Increase Charter Capital from Owner's Equity in 2026;

- Tờ trình số 07/Ttr – HĐQT về việc thông qua sửa đổi, bổ sung Ngành nghề kinh doanh của Công ty;

Proposal No. 07/Ttr – HĐQT on Approval of Amendments, Supplements to the Business Line of the Company;

- Tờ trình số 08/Ttr – HĐQT về việc thông qua thay đổi Điều lệ tổ chức và hoạt động của Công ty.

Proposal No. 08/Ttr – HĐQT on Approval of Amendments to the Company's Charter on the organization and operation.

- Tờ trình số 09/Ttr – HĐQT về việc thông qua các hợp đồng, giao dịch giữa Công ty Cổ phần Dược Vật tư Y tế Hải Dương với người có liên quan.

Proposal No. 09/Ttr – HĐQT on approval of the contracts, transactions between Hai Duong Pharmaceutical Medical Materials JSC and the related persons.

IV. THẢO LUẬN VÀ Ý KIẾN CỦA CỔ ĐÔNG/SHAREHOLDER DISCUSSION AND COMMENTS

- Chủ tọa mời các đại biểu tham dự Đại hội tham gia thảo luận các Báo cáo và Tờ trình được Đoàn chủ tọa trình bày.

The Chairman invited delegates to discuss the Reports and Proposals presented by the Presidium.

- Cổ đông không có câu hỏi nào dành cho Đoàn Chủ tọa.

Shareholders had no questions for the Presidium.

V. BIỂU QUYẾT CÁC VẤN ĐỀ THUỘC THẨM QUYỀN CỦA ĐẠI HỘI ĐỒNG CỔ ĐÔNG/VOTING ON MATTERS WITHIN THE JURISDICTION OF THE GENERAL MEETING OF SHAREHOLDERS

Sau khi nghe Bà Nguyễn Thị Hương Lan - Trưởng Ban kiểm phiếu hướng dẫn Đại hội biểu quyết, Đại hội đã tiến hành biểu quyết bằng hình thức bỏ phiếu kín.

After listening to Mrs. Nguyen Thi Huong Lan - Head of the Vote Counting Committee instructing the Congress on voting, the Congress proceeded to vote by secret ballot.

Tại thời điểm: 10 giờ, số lượng đại biểu dự họp là: **226** đại biểu, đại diện cho: **33.650.919** phiếu biểu quyết, chiếm: **93,48%** tổng số phiếu biểu quyết của tất cả cổ đông có quyền biểu quyết.

At: 10 am, the number of delegates attending the meeting was: 226 delegates, representing: 33,650,919 votes, accounting for: 93.48% of the total votes of all shareholders with voting rights.

Trong đó / *In which:*

- Tổng số tờ phiếu phát ra: **226**, đại diện cho **33.650.919** phiếu biểu quyết, chiếm **93,48%** tính

trên tổng số phiếu biểu quyết của cổ đông dự họp.

Total number of votes issued: 226 representing 33,650,919 votes, accounting for 93,48% of the total number of votes of shareholders attending the meeting.

- Tổng số tờ phiếu thu về: 226, đại diện cho 33.650.919 phiếu biểu quyết, chiếm 93,48% tính trên tổng số phiếu biểu quyết của cổ đông dự họp.

Total number of votes collected: 226 representing 33,650,919 votes, accounting for 93.48% of the total number of votes of shareholders attending the meeting.

- Tổng số tờ phiếu không thu về: 0, đại diện cho phiếu biểu quyết, chiếm 0,0000% tính trên tổng số phiếu biểu quyết của cổ đông dự họp.

Total number of votes not collected: 0 representing 0 votes, accounting for 0.0000% of the total number of votes of shareholders attending the meeting.

Kết quả kiểm phiếu biểu quyết cho từng nội dung như sau / The voting results for each content are as follows:

- **Nội dung 01: Thông qua Báo cáo hoạt động của Hội đồng quản trị năm 2025; Báo cáo hoạt động của Ban kiểm soát năm 2025; Báo cáo hoạt động sản xuất kinh doanh năm 2025 và kế hoạch năm 2026 theo Tờ trình số 01/Ttr-HĐQT của Hội đồng quản trị.**

Content 01: Approval of the Board of Directors' 2025 Operational Report; Board of Supervisors' 2025 Operational Report; 2025 Business and Production Activity Report and 2026 Plan according to Proposal No. 01/Ttr-HĐQT of the Board of Directors.

- Tổng số tờ phiếu hợp lệ: 226, đại diện cho 33.650.919 phiếu biểu quyết, chiếm 100,0000% tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết, trong đó:

Total number of votes collected: 226 representing 33,650,919 votes, accounting for 100.0000% of the total number of voting ballots of shareholders attending the meeting and casting their votes, of which:

- Tổng số tờ phiếu tán thành: 226 đại diện cho: 33.650.919 phiếu biểu quyết, chiếm: 100,0000% tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of votes in favor: 226 representing: 33,650,919 votes, accounting for 100.0000% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

- Tổng số tờ phiếu không tán thành: 0 đại diện cho: 0 phiếu biểu quyết, chiếm: 0,0000% tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of votes against: 0 representing: 0 votes, accounting for: 0.0000% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

- Tổng số tờ phiếu không có ý kiến: 0 đại diện cho: 0 phiếu biểu quyết, chiếm: 0,0000% tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of ballots with no opinion: 0 representing: 0 votes, accounting for: 0.0000% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

- Tổng số tờ phiếu không hợp lệ: 0 đại diện cho: 0 phiếu biểu quyết, chiếm: 0,0000% tính trên

tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of invalid ballots: 0 representing: 0 votes, accounting for: 0.0000% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

Như vậy, nội dung 01 đã được thông qua với tỷ lệ 100%

As a result, content 01 was approved with a rate of 100%.

- **Nội dung 02: Thông qua Báo cáo tài chính năm 2025 đã được kiểm toán theo Tờ trình số 02/Ttr-HĐQT của Hội đồng quản trị.**

Content 02: Approval of the audited 2025 Financial Report according to Submission No. 02/Ttr-HĐQT of the Board of Directors.

- Tổng số tờ phiếu hợp lệ: 226, đại diện cho 33.650.919 phiếu biểu quyết, chiếm 100,0000% tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết, trong đó:

Total number of votes collected: 226 representing 33,650,919 votes, accounting for 100.0000% of the total number of voting ballots of shareholders attending the meeting and casting their votes, of which:

- Tổng số tờ phiếu tán thành: 225 đại diện cho: 33.647.772 phiếu biểu quyết, chiếm: 99,99% tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of votes in favor: 225 representing: 33,647,772 votes, accounting for 99.99% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

- Tổng số tờ phiếu không tán thành: 0 đại diện cho: 0 phiếu biểu quyết, chiếm: 0,0000% tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of votes against: 0 representing: 0 votes, accounting for: 0.0000% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

- Tổng số tờ phiếu không có ý kiến: 01 đại diện cho: 3.147 phiếu biểu quyết, chiếm: 0,01% tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of ballots with no opinion: 01 representing: 3,147 votes, accounting for: 0.01% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

- Tổng số tờ phiếu không hợp lệ: 0 đại diện cho: 0 phiếu biểu quyết, chiếm: 0,0000% tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of invalid ballots: 0 representing: 0 votes, accounting for: 0.0000% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

Như vậy, nội dung 02 đã được thông qua với tỷ lệ 99,99%

As a result, content 02 was approved with a rate of 99.99%.

- **Nội dung 03: Thông qua Phương án phân phối lợi nhuận năm 2025 và dự toán tài chính năm 2026 theo Tờ trình số 03/Ttr – HĐQT của Hội đồng quản trị**

Content 03: Approval of the 2025 profit distribution plan and 2026 financial budget according to Proposal No. 03/Ttr – HĐQT of the Board of Directors

- Tổng số tờ phiếu hợp lệ: **226**, đại diện cho **33.650.919** phiếu biểu quyết, chiếm **100,0000%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết, trong đó:

Total number of votes collected: 226 representing 33,650,919 votes, accounting for 100.0000% of the total number of voting ballots of shareholders attending the meeting and casting their votes, of which:

- Tổng số tờ phiếu tán thành: **225** đại diện cho: **33.647.772** phiếu biểu quyết, chiếm: **99,99%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of votes in favor: 225 representing: 33,647,772 votes, accounting for 99.99% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

- Tổng số tờ phiếu không tán thành: **0** đại diện cho: **0** phiếu biểu quyết, chiếm: **0,0000%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of votes against: 0 representing: 0 votes, accounting for: 0.0000% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

- Tổng số tờ phiếu không có ý kiến: **01** đại diện cho: **3.147** phiếu biểu quyết, chiếm: **0,01%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of ballots with no opinion: 01 representing: 3,147 votes, accounting for: 0.01% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

- Tổng số tờ phiếu không hợp lệ: **0** đại diện cho: **0** phiếu biểu quyết, chiếm: **0,0000%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of invalid ballots: 0 representing: 0 votes, accounting for: 0.0000% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

Như vậy, nội dung 03 đã được thông qua với tỷ lệ 99,99%

As a result, content 03 was approved with a rate of 99.99%.

• **Nội dung 04: Thông qua việc chi trả thù lao cho HĐQT, BKS năm 2025 và đề xuất năm 2026 theo Tờ trình số 04/Ttr-HĐQT của Hội đồng quản trị.**

Content 04: Approval of remuneration payment for the Board of Directors and Board of Supervisors in 2025 and proposal for 2026 according to Proposal No. 04/Ttr-HĐQT of the Board of Directors.

- Tổng số tờ phiếu hợp lệ: **226**, đại diện cho **33.650.919** phiếu biểu quyết, chiếm **100,0000%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết, trong đó:

Total number of votes collected: 226 representing 33,650,919 votes, accounting for 100.0000% of the total number of voting ballots of shareholders attending the meeting and casting their votes, of which:

- Tổng số tờ phiếu tán thành: **224** đại diện cho: **33.643.274** phiếu biểu quyết, chiếm: **99,98%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of votes in favor: 224 representing: 33,643,274 votes, accounting for 99.98% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

- Tổng số tờ phiếu không tán thành: **0** đại diện cho: **0** phiếu biểu quyết, chiếm: **0,0000%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of votes against: 0 representing: 0 votes, accounting for: 0.0000% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

- Tổng số tờ phiếu không có ý kiến: **02** đại diện cho: **7.645** phiếu biểu quyết, chiếm: **0,02%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of ballots with no opinion: 02 representing: 7,645 votes, accounting for: 0.02% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

- Tổng số tờ phiếu không hợp lệ: **0** đại diện cho: **0** phiếu biểu quyết, chiếm: **0,0000%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of invalid ballots: 0 representing: 0 votes, accounting for: 0.0000% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

Như vậy, nội dung 04 đã được thông qua với tỷ lệ 99,98%

As a result, content 04 was approved with a rate of 99.98%.

- **Nội dung 05: Thông qua việc lựa chọn đơn vị kiểm toán BCTC năm 2026 theo Tờ trình số 05/Ttr-HĐQT của Hội đồng quản trị**

Content 05: Approval of the selection of the 2026 Financial Statements Auditing Unit according to Proposal No. 05/Ttr-HĐQT of the Board of Directors

- Tổng số tờ phiếu hợp lệ: **226**, đại diện cho **33.650.919** phiếu biểu quyết, chiếm **100,0000%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết, trong đó:

Total number of votes collected: 226 representing 33,650,919 votes, accounting for 100.0000% of the total number of voting ballots of shareholders attending the meeting and casting their votes, of which:

- Tổng số tờ phiếu tán thành: **225** đại diện cho: **33.647.772** phiếu biểu quyết, chiếm: **99,99%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of votes in favor: 225 representing: 33,647,772 votes, accounting for 99.99% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

- Tổng số tờ phiếu không tán thành: **0** đại diện cho: **0** phiếu biểu quyết, chiếm: **0,0000%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of votes against: 0 representing: 0 votes, accounting for: 0.0000% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

- Tổng số tờ phiếu không có ý kiến: **01** đại diện cho: **3.147** phiếu biểu quyết, chiếm: **0,01%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of ballots with no opinion: 01 representing: 3,147 votes, accounting for: 0.01% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

- Tổng số tờ phiếu không hợp lệ: **0** đại diện cho: **0** phiếu biểu quyết, chiếm: **0,0000%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of invalid ballots: 0 representing: 0 votes, accounting for: 0.0000% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

Như vậy, nội dung 05 đã được thông qua với tỷ lệ 99,99%

As a result, content 05 was approved with a rate of 99.99%.

- **Nội dung 06: Thông qua phương án phát hành cổ phiếu để tăng vốn cổ phần từ nguồn vốn chủ sở hữu năm 2026 theo Tờ trình số 06/Ttr-HĐQT của Hội đồng quản trị.**

Content 06: Approval of the plan for Issuing Shares to Increase Charter Capital from Owner's Equity in 2026 according to Proposal No. 06/Ttr-HDQT of the Board of Directors.

- Tổng số tờ phiếu hợp lệ: **226**, đại diện cho **33.650.919** phiếu biểu quyết, chiếm **100,0000%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết, trong đó:

Total number of votes collected: 226 representing 33,650,919 votes, accounting for 100.0000% of the total number of voting ballots of shareholders attending the meeting and casting their votes, of which:

- Tổng số tờ phiếu tán thành: **226** đại diện cho: **33.650.919** phiếu biểu quyết, chiếm: **100,0000%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of votes in favor: 226 representing: 33,650,919 votes, accounting for 100.0000% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

- Tổng số tờ phiếu không tán thành: **0** đại diện cho: **0** phiếu biểu quyết, chiếm: **0,0000%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of votes against: 0 representing: 0 votes, accounting for: 0.0000% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

- Tổng số tờ phiếu không có ý kiến: **0** đại diện cho: **0** phiếu biểu quyết, chiếm: **0,0000%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of ballots with no opinion: 0 representing: 0 votes, accounting for: 0.0000% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

- Tổng số tờ phiếu không hợp lệ: **0** đại diện cho: **0** phiếu biểu quyết, chiếm: **0,0000%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of invalid ballots: 0 representing: 0 votes, accounting for: 0.0000% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

Như vậy, nội dung 06 đã được thông qua với tỷ lệ 100%

As a result, content 06 was approved with a rate of 100%.

- **Nội dung 07: Thông qua sửa đổi, bổ sung Ngành nghề kinh doanh của Công ty.**

Content 07: Approval of Amendments, Supplements to the Business Sector of the Company

- Tổng số tờ phiếu hợp lệ: **226**, đại diện cho **33.650.919** phiếu biểu quyết, chiếm **100,0000%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết, trong đó:

Total number of votes collected: 226 representing 33,650,919 votes, accounting for 100.0000% of the total number of voting ballots of shareholders attending the meeting and casting their votes, of which:

– Tổng số tờ phiếu tán thành: **224** đại diện cho: **33.643.274** phiếu biểu quyết, chiếm: **99,98%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of votes in favor: 224 representing: 33,643,274 votes, accounting for 99.98% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

– Tổng số tờ phiếu không tán thành: **01** đại diện cho: **3.147** phiếu biểu quyết, chiếm: **0,01%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of votes against: 01 representing: 3.147 votes, accounting for: 0.01% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

– Tổng số tờ phiếu không có ý kiến: **01** đại diện cho: **4.498** phiếu biểu quyết, chiếm: **0,01%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of ballots with no opinion: 01 representing: 4.498 votes, accounting for: 0.01% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

– Tổng số tờ phiếu không hợp lệ: **0** đại diện cho: **0** phiếu biểu quyết, chiếm: **0,0000%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of invalid ballots: 0 representing: 0 votes, accounting for: 0.0000% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

Như vậy, nội dung 07 đã được thông qua với tỷ lệ 99,98%

As a result, content 07 was approved with a rate of 99.98%.

• **Nội dung 8. Thông qua thay đổi Điều lệ tổ chức và hoạt động của Công ty.**

Content 8: Approval of Amendments to the Company's Charter on the organization and operation

- Tổng số tờ phiếu hợp lệ: **226**, đại diện cho **33.650.919** phiếu biểu quyết, chiếm **100,0000%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết, trong đó:

Total number of votes collected: 226 representing 33,650,919 votes, accounting for 100.0000% of the total number of voting ballots of shareholders attending the meeting and casting their votes, of which:

– Tổng số tờ phiếu tán thành: **225** đại diện cho: **33.647.772** phiếu biểu quyết, chiếm: **99,99%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of votes in favor: 225 representing: 33,647,772 votes, accounting for 99.99% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

– Tổng số tờ phiếu không tán thành: **0** đại diện cho: **0** phiếu biểu quyết, chiếm: **0,0000%** tính trên

tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of votes against: 0 representing: 0 votes, accounting for: 0.0000% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

- Tổng số tờ phiếu không có ý kiến: **01** đại diện cho: **3.147** phiếu biểu quyết, chiếm: **0,01%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of ballots with no opinion: 01 representing: 3,147 votes, accounting for: 0.01% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

- Tổng số tờ phiếu không hợp lệ: **0** đại diện cho: **0** phiếu biểu quyết, chiếm: **0,0000%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of invalid ballots: 0 representing: 0 votes, accounting for: 0.0000% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

Như vậy, nội dung 08 đã được thông qua với tỷ lệ 99,99%

As a result, content 08 was approved with a rate of 99.99%.

- **Nội dung 9: Thông qua các hợp đồng, giao dịch giữa Công ty Cổ phần Dược Vật tư Y tế Hải Dương với người có liên quan**

Content 9: Proposal No. 10/Ttr – HĐQT on approval of the contracts, transactions between Hai Duong Pharmaceutical Medical Materials JSC and the related persons.

- Tổng số tờ phiếu hợp lệ: **226**, đại diện cho **33.650.919** phiếu biểu quyết, chiếm **100,0000%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết, trong đó:

Total number of votes collected: 226 representing 33,650,919 votes, accounting for 100.0000% of the total number of voting ballots of shareholders attending the meeting and casting their votes, of which:

- Tổng số tờ phiếu tán thành: **225** đại diện cho: **33.647.772** phiếu biểu quyết, chiếm: **99,99%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of votes in favor: 225 representing: 33,647,772 votes, accounting for 99.99% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

- Tổng số tờ phiếu không tán thành: **0** đại diện cho: **0** phiếu biểu quyết, chiếm: **0,0000%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of votes against: 0 representing: 0 votes, accounting for: 0.0000% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

- Tổng số tờ phiếu không có ý kiến: **01** đại diện cho: **3.147** phiếu biểu quyết, chiếm: **0,01%** tính trên tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of ballots with no opinion: 01 representing: 3,147 votes, accounting for: 0.01% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

- Tổng số tờ phiếu không hợp lệ: **0** đại diện cho: **0** phiếu biểu quyết, chiếm: **0,0000%** tính trên

tổng số phiếu biểu quyết của cổ đông dự họp và biểu quyết.

Total number of invalid ballots: 0 representing: 0 votes, accounting for: 0.0000% of the total number of voting ballots of shareholders attending the meeting and casting their votes.

Như vậy, nội dung 09 đã được thông qua với tỷ lệ 99,99%

As a result, content 09 was approved with a rate of 99.99%.

VI. THỦ TỤC BẾ MẠC ĐẠI HỘI / CLOSING PROCEDURES

- Bà Trần Thị Dương – Thư ký Đại hội đọc toàn văn dự thảo Biên bản họp và Nghị quyết ĐHĐCĐ thường niên năm 2026 cho toàn thể cổ đông dự họp cùng nghe.

Mrs. Tran Thi Duong - Secretary of the General Meeting read the full text of the draft Minutes and Resolution of the 2026 Annual General Meeting of Shareholders for all shareholders attending the meeting to listen to.

- Đại hội tiến hành biểu quyết thông qua Biên bản họp và Nghị quyết ĐHĐCĐ thường niên năm 2026 bằng hình thức giơ Thẻ biểu quyết.

The Congress voted to approve the Minutes and Resolution of the 2026 Annual General Meeting of Shareholders by raising Voting Cards.

- Đại hội đã nhất trí 100% thông qua toàn văn Biên bản họp và Nghị quyết ĐHĐCĐ thường niên năm 2026.

The Congress unanimously approved the full text of the Minutes and Resolution of the 2026 Annual General Meeting of Shareholders.

- Ông Nguyễn Trung Việt – Chủ tọa tuyên bố bế mạc Đại hội.

Mr. Nguyen Trung Viet - Chairman declared the closing of the General Meeting.

- Đại hội kết thúc vào hồi 12 giờ cùng ngày ./.

The meeting ended at 12 pm on the same day./.

THƯ KÝ

SECRETARY



TRẦN THỊ DƯƠNG

CHỦ TỌA

CHAIRMAN



NGUYỄN TRUNG VIỆT

Hai Phong, March 16th, 2026

REPORT OF THE BOARD OF DIRECTORS
SUBMITTED TO THE 2026 ANNUAL GENERAL MEETING OF
SHAREHOLDERS

Dear distinguished guests,

Dear shareholders of HDPHARMA,

In accordance with the Charter on Organization and Operation of **Hai Duong Pharmaceutical Medical Materials Joint Stock Company**, the Board of Directors hereby reports to the General Meeting of Shareholders on the operational activities of the Board of Directors in **2025** and outlines the operational orientation for the coming years as follows:

I. ACTIVITIES OF THE BOARD OF DIRECTORS IN 2025

1. Personnel of the Board of Directors

At the 2025 Annual General Meeting of Shareholders, the Board of Directors for the 2024–2029 term was elected by the shareholders. As of the reporting date, the Board of Directors consists of three members:

No	FULL NAME	POSITION
1	Nguyen Trung Viet	Chairman of the Board of Directors
2	Nguyen Thi Tu Anh	Member of the Board of Directors – General Director of the Company
3	Tran Phuc Duong	Member of the Board of Directors

All members of the Board of Directors attended all meetings (or provided written opinions when required) with a strong sense of responsibility. They effectively utilized their leadership capacity and professional expertise, always prioritizing the sustainable development of the Company and the interests of the shareholders.

The members of the Board of Directors successfully fulfilled their assigned duties, including:

- The Chairman of the Board of Directors fulfilled his functions, duties, authority and obligations in accordance with the Law on Enterprises, the Company Charter, and the Regulations on the operation of the Board of Directors.
- The members of the Board of Directors made positive contributions in management and supervision of the Company's business and production activities.

2. Activities of the Board of Directors

- The Board of Directors operates in accordance with the Charter on Organization and Operation of Hai Duong Pharmaceutical Medical Materials Joint Stock Company.
- Every year, the Board of Directors reports to the Annual General Meeting of Shareholders regarding its activities, particularly on the supervision of the Executive Director during the fiscal year.
- Two members of the Board of Directors, namely the Chairman and the General Director, directly participate in the Company's management and operational activities.

In 2025, the Board of Directors held fourteen (14) regular and extraordinary meetings to address key issues including: Implementation of the Resolution of the 2025 Annual General Meeting of Shareholders, Development and execution of the 2025 business and production plan, Review of the Company's development strategy, Consolidation of the Company's leadership and management personnel, Resolutions passed during these meetings served as important orientations for the Board of Management to implement the targets set by the General Meeting of Shareholders.

All meetings were convened and conducted in compliance with regulations, with 100% participation of Board members and high consensus on major decisions. The Head of the Supervisory Board was also invited to attend the meetings.

All resolutions and decisions were disclosed in accordance with current legal regulations.

3. Supervision and evaluation of the Board of Management and Company management departments

The Board of Directors regularly performs its supervisory duties over management personnel, requiring the executive apparatus to provide periodic and ad-hoc reports and promptly update any changes in production and business activities so that the Board of Directors can take timely measures when necessary. The Board also regularly reviews the production and business situation and makes prompt adjustments when required. As a result, all management staff have fulfilled their assigned duties.

– Supervision results regarding the Board of Management:

In compliance with the provisions of the Company Charter and the resolutions issued by the Board of Directors, the Board of Management has seriously, proactively, and promptly implemented the assigned tasks. They have accurately identified and assessed the challenges in business operations, thereby proposing and implementing timely and effective management measures in production and operations. The Board of Management has correctly identified and decisively focused on the strategic objectives approved by the General Meeting of Shareholders. They have complied with legal regulations and strictly adhered to reporting requirements, ensuring effective

management and operation as well as the safety of capital, assets, and occupational safety.

– Supervision results regarding management personnel:

Managers appointed by the Board of Directors upon the recommendation of the General Director have strictly performed the duties assigned by the General Director. They have effectively implemented management directives and decisions, ensuring that the Company's production and business activities meet the required objectives. There have been no signs of resistance or avoidance of responsibilities. At the same time, they have actively provided recommendations and proposals to enhance the effectiveness of task implementation. In 2025, middle-level managers (workshops and departments) were evaluated by the Board of Directors as having basically fulfilled their assigned duties.

– General assessment:

The activities of the Company's Board of Directors in 2025 complied with legal regulations and the Company Charter in performing its functions and duties. The resolutions and decisions issued by the Board of Directors were timely and contributed significantly to the effective management and direction of production and business activities, particularly in addressing difficulties in both business and production operations.

4. Remuneration of the Board of Directors: As stipulated in the Charter.

(The remuneration of the Board of Directors is disclosed in the audited 2025 financial statements presented to the General Meeting of Shareholders.)

II. IMPLEMENTATION OF RESOLUTIONS OF THE 2025 GENERAL MEETING OF SHAREHOLDERS

At the 2025 Annual General Meeting of Shareholders, the Board of Directors submitted 09 proposals, which were approved by the shareholders.

All approved matters have been and are being implemented in accordance with the issued resolutions.

However, up to the present time, one item in Proposal No. 08 — regarding the listing of DHD shares on the Ho Chi Minh City Stock Exchange / Vietnam Stock Exchange — has not yet been implemented.

The Board of Directors will complete the necessary conditions and submit it again to the General Meeting of Shareholders when appropriate conditions are met.

III. PERFORMANCE OF THE BOARD OF DIRECTORS IN 2025 AND FUTURE PLANS

The 2025 production and business results have been presented in detail in the report of the Board of Management. In this report, on behalf of the Board of Directors, I would like to highlight several issues of particular interest to shareholders:

- The Company's strategy
- The Company's growth
- The Company's shares

1. Company Strategy

In 2015, I wrote a 10-year strategic plan for HDPHARMA on behalf of the Board of Directors.

The analysis at that time indicated that regulatory authorities would gradually raise management standards and enforce stricter quality inspections. Consequently, pharmaceutical manufacturers would become differentiated, and companies failing to meet quality standards would be eliminated. Based on that perspective, the strategy clearly defined:

- Strengthening quality improvement and standardization, with EU-GMP as the core production standard
- Focusing on pharmaceutical product development
- Expanding the Company's own commercial products while gradually reducing outsourced manufacturing and trading of other companies' products

Up to now, these assessments and strategies have proven to be accurate, and the Company has achieved very positive results by following this strategic direction.

2. Strategy for the Next 10 Years

In principle, the next 10 years will continue following the existing strategy, with the primary objective of: Building additional EU-GMP compliant production lines, Modernizing pharmaceutical manufacturing, Making HDPHARMA one of the leading pharmaceutical companies in Vietnam

Specific plans:

- **At Factory No.1 (102 Chi Lang):**
 - + Replace the current injection line with a modern, higher-capacity system
 - + Invest in BFS production lines for ophthalmic drops, nasal sprays, and inhalation solutions
 - + Consider investing in liquid fermentation lines for oral medicines
- **At HDPHARMA EU Factory:**

- + Validate and operate 02 Cephalosporin production lines in Building 4C meeting EU-GMP standards
- + Begin design and construction of Building 4B with three EU-GMP compliant production lines
- + Construct Building 4D and a new office building
 - Optimize and further develop production on the Company's existing production lines;
 - Cooperate with partners and major global corporations to achieve breakthrough revenue growth;
 - Strengthen export activities;
 - Develop human resources;
 - Improve, modernize, and further develop the Company's business system.

3. Company Shares

The Company continues its strategy of gradually increasing charter capital to enhance corporate value, thereby increasing the value of the Company's shares. This strategy will remain unchanged this year.

In conclusion, the above summarizes the activities of the Board of Directors in 2025 and the operational orientation for the coming years.

Although many challenges remain ahead, all members of HDPHARMA, with enthusiasm, intelligence, and unity, will strive to achieve the established goals and turn the dream of making HDPHARMA a leading pharmaceutical enterprise into reality.

We sincerely thank the shareholders for their continued support and companionship throughout the past year.

Wishing all distinguished delegates and shareholders of HDPHARMA good health and a wonderful day.

Recipients:

- Company Shareholders;
- Members of the Board of Directors and Supervisory Board;
- Office archive.

**ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRMAN**



Nguyen Trung Viet

Hai Phong, March 11, 2026

**REPORT OF THE SUPERVISORY BOARD
AT THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS**

**Respectfully submitted to: The General Meeting of Shareholders of
Hai Duong Pharmaceutical Medical Materials Joint Stock Company.**

In 2025, in the context of continued fluctuations in both the domestic and global economies and increasingly intense competition in the pharmaceutical industry, Hai Duong Pharmaceutical Medical Materials Joint Stock Company made significant efforts to implement various solutions aimed at stabilizing production and business activities, improving corporate governance efficiency, and gradually implementing the Company's strategic development orientations.

The Board of Directors and the Board of Management proactively managed the Company's operations in accordance with the orientations approved by the General Meeting of Shareholders, focusing on strengthening financial capacity, improving production and business efficiency, expanding markets, and continuing to invest in the development of the Company's manufacturing system, particularly the HDPHARMA EU Factory project, in order to enhance competitiveness and create a foundation for sustainable development in the coming years. Pursuant to:

- The Law on Enterprises and relevant legal regulations;
- The Charter on Organization and Operation of Hai Duong Pharmaceutical Medical Materials Joint Stock Company;
- The 2025 financial statements of the Company prepared and audited in accordance with regulations;
- The authority and responsibilities of the Supervisory Board as stipulated in the Company's Charter;
- The results of supervision of the Board of Directors and the Board of Management during 2025;

In performing the duties assigned by the General Meeting of Shareholders, the Supervisory Board respectfully reports to the 2026 Annual General Meeting of Shareholders on the results of supervising the Company's operations in 2025 and the operational plan of the Supervisory Board for 2026.



I. ACTIVITIES OF THE SUPERVISORY BOARD IN 2025

The Supervisory Board of Hai Duong Pharmaceutical Medical Materials Joint Stock Company consists of three members elected by the General Meeting of Shareholders, operating in accordance with the Law on Enterprises, the Company's Charter, and relevant legal regulations.

During 2025, the Supervisory Board assigned specific responsibilities to each member and fully performed its supervisory functions and duties as prescribed. The activities of the Supervisory Board focused on supervising the governance activities of the Board of Directors, the management activities of the Board of Management, the Company's financial situation, and compliance with legal regulations and the Company's Charter throughout operations.

The Supervisory Board regularly monitored and inspected the implementation of resolutions of the General Meeting of Shareholders, decisions of the Board of Directors, and the execution of the Company's production and business plans. At the same time, it supervised the management and use of capital and assets to ensure that the Company's operations were conducted transparently, efficiently, and in compliance with regulations.

In 2025, the Supervisory Board performed the following activities:

- Supervising the Board of Directors and the Board of Management in managing and operating the Company's production and business activities;
- Monitoring the Company's financial situation, management and use of capital and assets, and the implementation of production and business targets as approved by the General Meeting of Shareholders;
- Supervising the implementation of resolutions of the General Meeting of Shareholders and decisions of the Board of Directors in the Company's production and business activities;
- Reviewing the legality, reasonableness, and accuracy of financial statements and production and business performance reports, and coordinating with the independent auditor during the financial audit process;
- Attending meetings of the Board of Directors and meetings of the Board of Management on important matters relating to production and business strategies to perform supervisory functions in accordance with regulations;
- Providing opinions on certain matters related to governance, management, and investment;
- Reviewing the issuance and implementation of internal management regulations and procedures to ensure the Company's operations comply with legal regulations and the Company's Charter.

In general, in 2025, the Supervisory Board fully performed its functions and duties in accordance with the law and the Company's Charter. Supervisory

activities were conducted regularly, contributing to ensuring that the Company's governance and management were carried out transparently, in compliance with regulations, and in protection of the legitimate rights and interests of shareholders.

II. SUPERVISION RESULTS OF THE COMPANY'S OPERATIONS

1. Financial Statements for 2025

Based on the audited 2025 financial statements of Hai Duong Pharmaceutical Medical Materials Joint Stock Company, the Supervisory Board notes the Company's financial situation as follows:

1.1 Financial Statement Figures

Unit: VND

No.	Indicators	Beginning of Year	End of Year
1	Total Assets	646,386,356,355	952,550,231,804
1.1	Current Assets	341,148,607,589	333,086,878,632
1.2	Non-current Assets	305,237,748,766	619,463,353,172
2	Total Capital	646,386,356,355	952,550,231,804
2.1	Liabilities	192,127,190,710	449,236,682,497
2.2	Equity	454,259,165,645	503,313,549,307

1.2 Production and Business Results

Unit: VND

Indicators	2025
1. Revenue from goods and services	689,532,822,613
2. Deductions	5,819,302,260
3. Net revenue	683,713,520,353
4. Cost of goods sold	438,734,362,525
5. Gross profit	244,979,157,828
6. Financial income	1,217,152,638
7. Financial expenses	5,681,886,282
8. Selling expenses	79,028,832,449
9. Administrative expenses	93,156,777,114
10. Operating profit	68,328,814,621
11. Other profit	1,436,746,884
12. Profit before tax	69,765,561,505
13. Corporate income tax expense	14,062,371,303
14. Profit after tax	55,703,190,202
15. Basic earnings per share	1,548

2. Review of Reports

2.1. Review of Financial Statements

Vietnam Auditing and Valuation Co., Ltd. (AVA) conducted the audit and issued an unqualified opinion on the financial statements for the fiscal year 2025. The Supervisory Board actively coordinated with the auditor to review and discuss comments and verify the audit contents. On that basis, we agree with the auditor's opinion that the financial statements fairly and accurately present, in all material respects, the Company's financial position as of December 31, 2025, as well as its business results and cash flows for the fiscal year, in accordance with Vietnamese Accounting Standards, the Vietnamese accounting regime, and relevant legal regulations on the preparation and presentation of financial statements. Main observations include:

- The 2025 financial statements fully reflect the Company's production and business operations and comply with regulations regarding reporting formats and deadlines.
- Accounting records and books are maintained in accordance with regulations issued by the Ministry of Finance.
- Accounting documents and records are properly prepared, stored systematically, and easily traceable for inspection and audit purposes.
- Financial reporting and information disclosure to shareholders and the State Securities Commission are carried out in compliance with legal regulations.

2.2. Review of the Production and Business Performance Report of the Board of Management

The Supervisory Board has reviewed the Report on the 2025 production and business performance submitted by the Board of Management. Based on a comparison with the figures presented in the audited financial statements and other relevant documents, the Supervisory Board finds that the report of the Board of Management has fully and accurately reflected the Company's production and business operations in 2025.

The Company's total revenue in 2025 reached VND 689,532,822,613. Profit before tax reached VND 69,765,561,505, and profit after tax reached VND 55,703,190,202, representing a growth of 37.17% compared to the previous year. These results demonstrate the Company's considerable efforts in maintaining stable production and business operations while gradually improving operational efficiency and profitability.

The Supervisory Board recognizes that the indicators presented in the Report on production and business performance of the Board of Management are consistent with the figures stated in the audited 2025 financial statements and have been prepared in compliance with current legal regulations and applicable

accounting standards. On that basis, the Supervisory Board agrees with the contents of the 2025 production and business performance report of the Board of Management.

2.3. Review of the Report on Activities of the Board of Directors

Based on the Report on the activities of the Board of Directors, the Supervisory Board recognizes that the Board of Directors has properly performed its functions, duties, and authority in accordance with the Law on Enterprises, the Company's Charter, and the resolutions of the General Meeting of Shareholders.

During 2025, the Board of Directors directed and supervised the Board of Management in organizing and implementing the Company's production and business activities, as well as in carrying out the objectives and plans approved by the General Meeting of Shareholders. The governance decisions of the Board of Directors were consistent with the Company's development orientations and complied with the current legal regulations.

The Supervisory Board notes that the Report of the Board of Directors fully reflects the Company's governance activities and management orientations in 2025. On that basis, the Supervisory Board agrees with the contents of the 2025 Activity Report of the Board of Directors.

3. Supervision of the Implementation of the 2025 General Meeting of Shareholders' Resolution

The Supervisory Board has supervised the implementation of the Resolution of the 2025 General Meeting of Shareholders by the Board of Directors and the Board of Management.

- Implementation of production and business plan targets:

+ Total revenue: VND 689,532,822,613, reaching 83.08% of the planned target, increasing 3.21% compared to 2024, equivalent to VND 21,476,634,371.

+ Total production value: VND 382,452,964,474, reaching 80.35% of the planned target, increasing 9.23% compared to 2024, equivalent to VND 32,330,914,838.

+ Profit after tax: VND 55,703,190,202, reaching 146.59% of the target approved by the General Meeting of Shareholders, increasing 37.17% compared to 2024, equivalent to VND 15,094,409,506.

- In 2025, basic earnings per share (EPS) amounted to VND 1,548 per share.
- In 2025, the Company implemented a share issuance to increase charter capital from equity sources in accordance with the Resolution of the General Meeting of Shareholders at a rate of 28.8%, with a total value of VND 80,486,120,000, equivalent to 8,048,612 shares. The Company also completed the securities depository registration for these shares, ensuring shareholders' rights in trading shares on the UPCOM market.

- In 2025, the Company paid cash dividends for 2024 at a rate of 2.2%, amounting to VND 6,148,409,740, in accordance with the Resolution of the General Meeting of Shareholders.
- Funds were appropriated in accordance with the profit distribution plan approved by the General Meeting of Shareholders.
- The Company selected Vietnam Auditing and Valuation Co., Ltd. (AVA) to conduct the semi-annual financial statement review and the audit of the 2025 financial statements, in accordance with the Securities Law and regulations of the State Securities Commission.
- Remuneration paid to the Board of Directors was 3% and to the Supervisory Board was 1% of profit after corporate income tax, in accordance with the Company's Charter and the Resolution of the General Meeting of Shareholders.
- As of the end of 2025, the charter capital was VND 359,959,290,000, an increase of VND 80,486,120,000 (equivalent to 28.8%) compared to 2024. This increase resulted from the issuance of shares from equity sources in accordance with the Resolution of the 2025 General Meeting of Shareholders.
- In 2025, the Company completed approximately 95% of the construction and installation of machinery and production lines under Phase 2 of the project, while continuing preparations for the implementation of Phase 3 of the HDPHARMA EU Factory project.
- In 2025, the Company established a subsidiary: Hai Duong Pharmaceutical Medical Materials Co., Ltd., with 100% owned capital. The Company is currently completing the necessary procedures to obtain the Certificate of Eligibility for Pharmaceutical Business Operations in order to commence operations in accordance with its registered business lines.
- In 2025, the Company did not carry out the listing of DHD shares on the Ho Chi Minh City Stock Exchange or the Vietnam Stock Exchange, due to incomplete legal procedures related to Hai Duong Pharmaceutical Medical Materials Co., Ltd.

III. EVALUATION OF COORDINATION BETWEEN THE SUPERVISORY BOARD, THE BOARD OF DIRECTORS, THE BOARD OF MANAGEMENT, AND SHAREHOLDERS

In 2025, the Supervisory Board closely coordinated with the Board of Directors and the Board of Management in performing its assigned duties. The Board of Directors and the Board of Management created favorable conditions for the Supervisory Board to carry out its tasks by providing relevant information and documentation related to the Company's operations. The Supervisory Board also coordinated with the Board of Directors and the Board of Management in inspection and supervision activities at the Company's branches and within the overall management system of the Company, thereby enabling timely solutions

to existing issues to improve management efficiency and ensure full compliance with applicable state regulations.

During 2025, the Supervisory Board did not receive any opinions or recommendations from shareholders. The Supervisory Board participated fully in meetings of the Board of Directors concerning the management and operation of the Company's production and business activities. Recommendations made by the Supervisory Board were considered and implemented by the Board of Directors and the Board of Management to ensure the interests of the Company and compliance with legal regulations.

The Board of Directors directed and closely supervised the Company's production and business operations. The Board of Management performed its duties and responsibilities in accordance with the Law on Enterprises and the current Company Charter. The Board of Management promptly implemented resolutions and decisions of the General Meeting of Shareholders and the Board of Directors, and regularly reported to the Board of Directors to seek guidance when necessary in accordance with regulations.

The coordination among the Supervisory Board, the Board of Directors, the Board of Management, and shareholders has been carried out on the principle of ensuring the Company's stability, sustainable development, and protection of shareholders' lawful rights and interests in accordance with legal regulations and the Company's Charter.

IV. OPERATIONAL PLAN OF THE SUPERVISORY BOARD FOR 2026

- Supervising the implementation of resolutions approved by the General Meeting of Shareholders;
- Supervising compliance with laws, the Company's Charter, and internal regulations in corporate management and operations;
- Supervising the financial situation, capital balance, cash flow management, operational efficiency, debt repayment capability, and the management and preservation of capital;
- Reviewing quarterly, semi-annual, and annual financial statements;
- Inspecting the legality, reasonableness, transparency, and prudence in business management and operations;
- Supervising the establishment and implementation of cost norms;
- Supervising the effectiveness of investment projects, bidding, and procurement activities;
- Supervising the procurement of raw materials, auxiliary materials, tools, equipment, and other goods;
- Supervising the implementation of recommendations from inspection teams and independent auditors (if any);
- Coordinating in the supervision of internal audit activities, reviewing and evaluating the effectiveness and efficiency of the internal control system,

- risk management, and early warning mechanisms in order to enhance the internal control system;
- Performing other duties of the Supervisory Board in accordance with the Law on Enterprises.

V. PROPOSALS AND RECOMMENDATIONS

In order for the Company to achieve the targets approved by the General Meeting of Shareholders for 2026 and to minimize risks in the Company's production and business operations, the Supervisory Board proposes the following recommendations:

1. Continuously improve governance and management activities, ensuring favorable conditions to maximize the capabilities of the management team so that the Company can develop stably and achieve or exceed the production, business, and profit targets approved by the General Meeting of Shareholders, thereby ensuring maximum lawful benefits for the Company and its shareholders.
2. Continue to improve and complete existing systems of internal procedures and regulations in compliance with the Law on Enterprises, the Company's Charter, relevant regulations, and internal documents in accordance with practical operational conditions to ensure effective business operations.
3. Strengthen inspection and supervision of the quality of raw materials, semi-finished products, and finished products.
4. Continuously upgrade and modernize machinery and equipment in production lines in order to improve productivity and product quality.
5. Consolidate and develop the supply chain, production, and sales systems, and further strengthen supervision of sales activities in accordance with established regulations while developing appropriate business strategies when introducing products to the market.
6. Enhance professional capacity in research and development (R&D) activities.
7. Develop appropriate plans to fully utilize the production capacity of the HDPHARMA EU factory, especially for products with competitive advantages produced on EU-GMP production lines.
8. Expand export markets to more countries around the world.

Distinguished Shareholders,

The above presents the report on the performance of the Supervisory Board in 2025. At the 2026 Annual General Meeting of Shareholders, the Supervisory Board respectfully submits this report to the General Meeting.

On behalf of the Supervisory Board, I would like to sincerely thank all shareholders for their continued trust and support over the past year.

We would also like to express our sincere appreciation to the Board of Directors, the Board of Management, departments, workshops, and branches for their cooperation with the Supervisory Board in enabling us to fulfill the duties assigned by the General Meeting of Shareholders.

We wish all distinguished delegates and shareholders good health, happiness, and success. We wish the Company continued development and the General Meeting great success.

Respectfully submitted!

Recipients:

- General Meeting of Shareholders;
- Board of Directors, Board of Management of the Company;
- Supervisory Board;
- Archived by the General Meeting Organizing Committee.

**ON BEHALF OF THE SUPERVISORY BOARD
HEAD OF THE SUPERVISORY BOARD**



Phạm Thi Thuy



Hai Phong, March 13th 2026

**REPORT ON THE 2025 PRODUCTION AND BUSINESS PERFORMANCE
PRESENTED TO THE 2026 ANNUAL GENERAL MEETING OF
SHAREHOLDERS**

*Distinguished guests and honored delegates,
Dear shareholders attending the General Meeting,*

As customary, in April every year, enterprises across the country organize their Annual General Meetings of Shareholders, marking the beginning of a new AGM season. Today, April 7th, 2026, Hai Duong Pharmaceutical Medical Materials Joint Stock Company, under the brand name HDPHARMA, convenes the 2026 Annual General Meeting of Shareholders to review and approve the report on the production and business performance in 2025, and to set out the objectives, tasks, and targets for production and business activities in 2026.

We are honored to welcome distinguished delegates, honored guests, and all shareholders of Hai Duong Pharmaceutical Medical Materials Joint Stock Company to today's Meeting. We would like to extend our best wishes to all distinguished guests and shareholders for the Year of the Horse 2026, wishing you abundant health, happiness, and success.

Distinguished delegates, honored guests, and esteemed shareholders of the Company!

We have now passed through the year 2025, a year marked by numerous global and domestic changes and unexpected events. The United States government increased tariffs and applied reciprocal tariffs on import and export goods with most countries. Foreign exchange rates fluctuated unpredictably, the global economy experienced downturns, and natural disasters occurred frequently with devastating impacts. In addition, regional conflicts in Eastern Europe between Russia and Ukraine and tensions in the Middle East have contributed to a global crisis affecting the economy, politics, and the environment. Vietnam, like many countries in

Southeast Asia, has faced significant challenges in maintaining political stability and macroeconomic balance. Businesses have been heavily affected and encountered severe difficulties in all aspects of production and business activities, investment conditions, and rising inflation. Many enterprises have been forced to suspend operations or initiate dissolution procedures, particularly small and medium-sized enterprises. Hai Duong Pharmaceutical Medical Materials Joint Stock Company, as a medium-sized local enterprise, has therefore been deeply affected by these circumstances. However, the 6th Term General Meeting of Shareholders established appropriate strategies, policies, and solutions. As a result, the Company has been able to maintain stability and continue its development. Planned production and business projects have continued to be implemented and expanded on the basis of the Company's established strategy and existing infrastructure. At the same time, the Company has consistently promoted innovation and improvement in order to develop a more modern and synchronized manufacturing system for pharmaceuticals, cosmetics, and health supplements. This system is designed to meet the stringent requirements of EU-GMP and WHO-GMP standards, ensuring high product quality to meet the needs of distribution and retail markets. As a result, revenue has increased, costs have been controlled, business performance has remained stable, and positive profit growth has been maintained. These achievements ensure the interests of shareholders, improve the livelihoods of company personnel, fulfill tax obligations to the State, and contribute actively to social and community programs.

This achievement has been made possible through the dedication, efforts, and contributions of the Board of Directors, all shareholders, and the entire personnel of the Company. In particular, the 6th General Meeting of Shareholders adopted important resolutions on strategic directions, policies, and appropriate solutions. Under the leadership of the Board and with the united efforts of all personnel, the Company has worked together with determination and solidarity to effectively implement the production and business plan for the fiscal year 2025.

Distinguished delegates, honored guests, and esteemed shareholders! In order to review and evaluate the results of the Company's production and business

activities in 2025, and to set out the objectives and tasks for the fiscal year 2026, Hai Duong Pharmaceutical Medical Materials Joint Stock Company convenes today's Annual General Meeting to discuss and determine more specific, comprehensive, and clearly defined goals and directions for the coming year.

Part I. Results Achieved

Regarding this matter, I would like to present the key indicators and most important figures that investors and shareholders are particularly concerned about. In my capacity as General Director, performing the functions and duties stipulated under the Law on Enterprises, the Company Charter, and the assignment of the Board of Directors, I am directly responsible for leading, managing, and operating the Company, as well as implementing all targets set by the Board of Directors. Accordingly, I would like to further elaborate on the data presented in the tables and charts, which have been duly audited, in order to provide shareholders and all participants of the Meeting with a clearer understanding of the Company's achievements and the substance of its business activities. These results represent the outcome of considerable effort and dedication, reflecting not only the challenges that the Company has overcome but also the collective intelligence, commitment, and contributions of all personnel, together with the continued support and trust of the Company's shareholders.

Production and Business Performance in 2025

To provide an overall picture of the implementation of the production and business plan in 2025, we respectfully invite the distinguished delegates, honored guests, and all shareholders attending the Meeting to review the audited Financial Statements for the year 2025, which include:

1. Report of the Board of Management
2. Report of the Auditor
3. Balance Sheet as at December 31st 2025
4. Statement of Business Operations for the Year 2025
5. Statement of Cash Flows for the Year 2025
6. Notes to the Financial Statements for the Year 2025

Distinguished delegates, honored guests, and shareholders!

All of these reports are based on accurate and up-to-date data that have been verified by Vietnam Auditing and Valuation Co., Ltd. In 2025, the Company signed an audit engagement contract with Vietnam Auditing and Valuation Co., Ltd. to conduct the audit in accordance with professional practices and the applicable regulations of Vietnamese law. The Independent Auditor’s Report has reviewed and verified the financial data prepared by the Company in an open and transparent manner. The financial statements presented to this Meeting therefore ensure truthfulness, accuracy, and compliance with the current Vietnamese Accounting Standards, the Vietnamese enterprise accounting regime, and other relevant legal regulations governing the preparation and presentation of financial statements. The audited financial statements have been submitted to the State Securities Commission and publicly disclosed on the Company’s website at hdpharma.vn in accordance with the prescribed timeline, as stipulated in Circular No. 96/2020/TT-BTC and Circular No. 68/2024/TT-BTC of the Ministry of Finance.

1. Results of the Implementation of the 2025 Production Plan

Unit: VND

No.	Production Department	Actual	% of Annual Plan	
			Plan	% of Plan
1	OSD LINE 1 - EU	37,393,974,261	62,000,000,000	60.31
2	OSD LINE 2 - WHO	18,545,470,481	27,500,000,000	67.44
3	HERBAL EXTRACTION	36,628,233,976	45,000,000,000	81.40
4	CREAM - OINTMENT - SOLUTION	22,208,042,372	22,500,000,000	98.70
5	SOFTGEL	92,627,998,583	100,000,000,000	92.63
6	ORAL AMPOULE	7,865,224,247	14,000,000,000	56.18
7	INJECTABLES - NASAL DROPS	91,852,669,597	115,000,000,000	79.87
8	OSD LINE (102 CHI LANG)	75,331,350,957	90,000,000,000	83.70
	Total	382,452,964,474	476,000,000,000	80.35

Accordingly, compared with the production plan target of VND 476 billion for 2025, the actual production value achieved 80.35% of the planned target, representing a shortfall of 19.65% against the plan. However, compared with 2024, production value increased by 9.2%, equivalent to VND 32.330 billion.

2. Results of the Business Plan Implementation

Some indicators in the audited financial statements for 2025:

NO.	INDICATOR	AMOUNT (VND)
1	Total Assets	952,550,231,804
2	Equity:	503,313,549,307
2.1	<i>Owner's Contributed Capital</i>	<i>359,959,290,000</i>
2.2	<i>Development Investment Fund</i>	<i>79,594,214,888</i>
2.3	<i>Undistributed Profit After Tax</i>	<i>63,760,044,419</i>
2.4.1	<i>Undistributed Profit After Tax from Previous Years</i>	<i>8,425,031,277</i>
2.4.2	<i>Undistributed Profit After Tax for Current Year</i>	<i>55,335,013,142</i>
3	Revenue from Sales of Goods and Provision of Services	689,532,822,613
4.	Deductions from Revenue	5,819,302,260
5	Total Net Revenue and Other Income	686.913.714.887
5.1	<i>Net Revenue from Sales of Goods and Provision of Services</i>	<i>683,713,520,353</i>
5.2	<i>Income from Financial Activities</i>	<i>1,217,152,638</i>
5.3	<i>Other Income</i>	<i>1,983,041,896</i>
6	Total Costs	617,148,153,382
6.1	<i>Cost of Goods Sold</i>	<i>438,734,362,525</i>
6.2	<i>Finance Costs</i>	<i>5,681,886,282</i>
6.3	<i>Selling Costs</i>	<i>79.028.832.449</i>

NO.	INDICATOR	AMOUNT (VND)
6.4	<i>Administrative Costs</i>	93,156,777,114
6.5	<i>Other cost</i>	546,295,012
7	Total Accounting Profit Before Tax	69,765,561,505
8	Current Corporate Income Tax cost	14,062,371,303
9	Profit After Corporate Income Tax	55,703,190,202
10	Basic Earnings per Share	1,548

- Total revenue after deducting internal revenue amounted to VND 689,532,822,613. Compared with the business plan for 2025, this represents 83% of the planned target and an increase of 3.2% compared with 2024, equivalent to VND 21,476,634,371

- Profit before corporate income tax amounted to VND 69,765,561,505, representing an increase of 37.36% compared with 2024, equivalent to VND 18,977,052,832

- Corporate income tax payable: VND 14,062,371,303

- Profit after corporate income tax amounted to VND 55,703,190,202, representing 146.5% of the 2025 plan and an increase of 37.2% compared with 2024, equivalent to VND 15,094,409,506.

Assessment of the Results for 2025:

Accordingly, it can be seen that in 2025, the Company exceeded the planned target for profit after corporate income tax, but did not fully achieve the targets for production value and business revenue as set out in the Resolution of the General Meeting of Shareholders.

Reasons:

+ The global economy in general, and Vietnam's economy in particular, continues to face significant challenges, with a slow pace of recovery. Supply chains have been frequently disrupted due to the Russia-Ukraine war and prolonged territorial conflicts in the Middle East. In addition, the United States has imposed higher import-export tariffs on goods from most countries. Foreign exchange rates

have increased unusually and remained unstable, while purchasing power in both domestic and international markets has declined significantly.

+ Contract manufacturing customers have also faced difficulties due to increased competition and the impact of the economic slowdown, particularly those placing orders for health supplement products. In 2025, the health supplement product segment was significantly affected by a crisis of consumer confidence, leading to a notable decline in revenue.

+ The EU-GMP production line has manufactured a considerable number of products; however, it did not fully achieve the planned targets because the line underwent revalidation during the year, which required additional time for qualification and for obtaining the EU-GMP certification as well as the official announcement from the Drug Administration of Vietnam.

3. Financial Management

+ Working capital: In 2025, the Company maintained the preparation of monthly budget plans, thereby enabling appropriate measures in utilizing financial resources for payments, accelerating capital turnover, and maintaining balanced cash flows. At the same time, the Company secured working capital loans at reasonable interest rates, which helped reduce borrowing costs and optimize financial expenses in production and business operations.

+ Project capital:

The Company has signed a medium-term loan agreement with BIDV Bank to ensure timely funding for the HDPHARMA Factory Phase 2 construction project. The total estimated investment cost of the project is VND 415 billion, including VND 256 billion in medium-term bank loans and VND 159 billion in the Company's own capital. As of December 31st 2025, the amount of medium-term loan disbursed by the bank for the project reached VND 235 billion.

+ State budget contributions:

In 2025, the Company fully and timely fulfilled its obligations to the State budget, including the payment of all applicable taxes, social insurance, health insurance, unemployment insurance, and trade union contributions in accordance with the prescribed regulations.

+ Total taxes paid: VND 33,976,600,683, representing 136% compared with 2024.

+ Total insurance contributions paid: VND 15,140,077,783.

+ Trade union contributions paid: VND 949,434,620.

4. Investment in Fixed Asset Acquisition

In 2025, the Company invested in advanced machinery and equipment and upgraded its facilities to support the revalidation of WHO-GMP certification, with the aim of increasing production capacity and improving product quality. The total investment in machinery and equipment for production and management activities amounted to VND 8,415,876,014.

5. Long-term Investment

In 2025, the Company continued implementing Phase 2 of the HDPHARMA EU Plant Project – Hai Duong Pharmaceutical Medical Materials Joint Stock Company in Cam Thuong, which includes the construction of two pharmaceutical production lines: sterile powder injection and Beta-lactam tablet lines for Cephalosporin antibiotics, meeting EU-GMP standards. The project commenced in June 2024 and is expected to be completed in 2026.

As of March 31st 2026, the project had completed approximately 95% of the total work volume. The Company has disbursed payments for consultancy, construction, and machinery and equipment installation contracts totaling VND 384 billion, of which VND 149 billion was financed from the Company's own capital and VND 235 billion from medium-term bank loans.

6. Depreciation of Fixed Assets, Allocation of Tools and Equipment, and Amortization of Prepaid Expenses

+ In 2025, the depreciation of fixed assets recognized and allocated amounted to VND 27,906,453,997, representing an increase of VND 635,423,932 compared with 2024. This increase was mainly due to newly invested assets being put into operation and subject to depreciation.

+ In 2025, the allocation of tools and equipment, prepaid expenses, and repair costs serving the revalidation process amounted to VND 7,057,072,831.

7. Financial Management and Professional Operations

+ In 2025, financial management continued to be strengthened through the establishment and implementation of standardized systems, operational procedures,

and financial management regulations applied consistently throughout the Company. Principles governing revenue and expenditure, procurement procedures, and price appraisal processes have been further refined and improved. Financial management has been carried out in a manner that ensures transparency, accuracy, and openness. The utilization of capital in production and business operations has always been purposeful, cost-efficient, and effective.

+ The management of accounts receivable has been further strengthened and tightened. The classification, monitoring, and follow-up of payments have been regularly coordinated among the Sales Department, Accounting Department, and the collection unit. Firm measures have been implemented to align sales activities with payment collection, tailored to each group of customers. As a result, overdue receivables and receivables exceeding credit limits have decreased significantly, while receivables from contract manufacturing and export customers have been effectively controlled.

+ In 2025, the Company effectively balanced its financial resources, ensuring sufficient and timely funding for Phase 2 of the investment project, as well as for production and business operations and the storage of goods and raw materials. The Company also made use of preferential credit packages with interest rate support from BIDV and VietinBank, while flexibly managing bank deposits and funds in payment circulation in order to enhance the efficiency of its financial operations.

+ The Company has effectively carried out monthly and quarterly financial reporting and analysis, providing timely information to support the Board of Directors and the Board of Management in managing and directing the Company's production, business, and investment activities. Accounting operations have been organized in a systematic and professional manner, meeting the requirements of the Company's financial management and accounting practices. The Company has also strictly complied with the Accounting Law and the applicable accounting standards.

Part II. Vision, Strategy, and Corporate Policies for 2026 and the Following Years

Distinguished delegates, honored guests, and esteemed shareholders!

As we are all aware, the current global situation, including developments in Southeast Asia, continues to be affected by conflicts, wars, and territorial disputes occurring in various countries and regions. These situations are becoming increasingly complex and unpredictable, exerting profound impacts on both domestic and international markets. Within Vietnam, although the Party and the Government have introduced a series of policies and initiatives aimed at facilitating economic flows, reducing administrative procedures, and promoting investment and trade both domestically and internationally, significant challenges remain. In particular, the issuance of Central Committee Resolution No. 29 and Resolution No. 30 has marked an important milestone for the advancement of science, technology, innovation, and national digital transformation, thereby creating new momentum for the development of legitimate enterprises. By fully understanding the Party's leadership orientation and the Government's direction and administration, authorities at all levels—from ministries and provincial departments to healthcare institutions—together with pharmaceutical enterprises, hospitals, and the domestic pharmaceutical sector, have continued to maintain stable production, supply, and distribution of medicines. Despite facing many difficulties and intense competition from both domestic companies and foreign or foreign-invested enterprises, the industry has ensured the adequate supply of medicines to meet the needs of disease prevention, medical treatment, and public health improvement, thereby contributing effectively to national healthcare programs.

As noted in the above assessment, Hai Duong Pharmaceutical Medical Materials Joint Stock Company has been operating in a context of considerable difficulties and challenges that have had widespread impacts. These circumstances can be considered potential risks affecting all aspects of operations, including production, distribution, import, and export activities, which are essential for maintaining the stable operation of a pharmaceutical enterprise in the current environment.

I would like to present the key risks, challenges, opportunities, and favorable factors for our consideration in order to determine the Company's strategy and policies for 2026 and the following years.

1. Opportunities: Although the business environment remains volatile and unpredictable, the domestic pharmaceutical sector continues to maintain growth and relative stability. Vietnam is currently classified as a lower-middle-income developing country, and the population is entering a rapid aging phase. This demographic trend is

leading to a growing demand for medicines used in the treatment of chronic diseases such as cardiovascular disorders and metabolic diseases. Consequently, the scale and structure of the pharmaceutical and health supplement markets are becoming increasingly defined and expanding over time.

The Government has issued a number of policies to support the development of the pharmaceutical industry, and the State encourages the use of domestically manufactured medicines within the drug procurement and bidding systems of hospitals and healthcare facilities. This policy direction creates favorable conditions for HDPHARMA to further research and develop product lines that are more aligned with market demand.

At present, the Company has successfully manufactured pharmaceutical products that meet EU-GMP standards, creating strong potential for export expansion into new markets, including Southeast Asia, Africa, and Middle Eastern countries.

2. Amid the fluctuations of the global economy and intense competition in the domestic market, the Company faces significant challenges. Major pharmaceutical enterprises such as DHG Pharma, Traphaco, and Imexpharm are well-established market leaders with strong advantages in brand reputation, financial capacity, and advanced technology. In particular, many of these companies benefit from investment by foreign shareholders from developed countries such as Germany, Japan, and South Korea, which further strengthens their competitive position.

Raw material and input costs remain highly volatile. A large proportion of production materials is sourced from foreign suppliers, and fluctuations in global oil prices due to geopolitical conflicts have affected both exchange rates and purchasing prices, creating significant challenges for enterprises.

Today, Vietnam is increasingly integrating into the global economy and aligning with international practices. Pharmaceutical and health supplement products are therefore required to meet very high standards and are subject to strict regulatory control. Accordingly, for the Company to sustain and develop, it is necessary to implement major investment strategies in advanced technologies, modern machinery and equipment, and highly sophisticated quality management systems. In terms of management and operations, such requirements demand substantial financial resources, which can be particularly challenging for small and medium-sized enterprises to meet.

Strengths of the Company:

The Company has a long-standing history, established in 1961, and is recognized as a well-established pharmaceutical enterprise within the Vietnamese pharmaceutical industry.

The Company has branches and a distribution network covering the entire country.

The Company has a team of experienced personnel who effectively perform management and operational duties in production, business operations, import-export activities, and the storage and preservation of goods.

The Company has implemented, is currently implementing, and will continue to implement investment plans to build production lines meeting EU-GMP and WHO-GMP standards at No. 307, Cam Thuong Industrial Cluster, Thanh Dong Ward, Hai Phong City.

Part III. Directions, Targets, and Key Tasks for the 2026 Financial Year

Distinguished delegates, honored guests, and respected shareholders!

Under the 2026 production and business plan, the Company has set a target of VND 840 billion in total revenue, including internal revenue, with production value expected to reach VND 518 billion and profit targeted at VND 45 billion. To achieve these targets, the entire Company must make strong and concerted efforts supported by specific and effective solutions.

The guiding principle for building the HDPHARMA brand is to affirm its value through top-quality products, high-standard manufacturing, and effective services implemented through the best standardized processes, while delivering the highest level of customer service and maximizing benefits for users.

In order to implement the Company's strategic development objectives and achieve the expected outcomes in economic performance, employee welfare, social responsibility, operational safety, and sustainable development.

1. Investment and Production Development Strategy

The Company will continue to invest in and complete Phase II of the factory project. The key focus for 2026 is to finalize and submit the cephalosporin injection and

tablet production lines for evaluation to achieve EU-GMP certification. At the same time, the Company will continue to maintain and effectively utilize the existing production lines that already meet EU-GMP and WHO-GMP standards, while optimizing operational processes and minimizing production costs.

Maximize the use of data related to production time and the operational capacity of machinery and equipment. Establish flexible production schedules to enhance efficiency and labor productivity while ensuring on-time delivery. Adjust production output appropriately based on market analysis, including sales data trends, socio-economic factors, market competition, and bidding activities, in order to more accurately forecast future product demand.

2. Supply Chain Management and Product Development Strategy

- Forecast demand based on the analysis of historical data on product usage and consumption, together with market trends and influencing factors.

- Optimize sourcing and supply: Improve transportation and logistics efficiency by selecting optimal routes and effectively monitoring and managing transport vehicles, thereby reducing delivery time and transportation costs.

- Automation of the procurement process: Utilize AI technologies to process large volumes of data from multiple sources, such as purchase history, supplier information, and pricing data, in order to analyze, compare, and identify the most suitable partners in terms of quality, delivery time, and cost. At the same time, strengthen the management of procurement contracts with suppliers to ensure proper compliance with contractual agreements.

- Focus on the production and development of essential medicines, particularly in the therapeutic areas of gastrointestinal and cardiovascular diseases, antibiotics, and anti-diabetic medications.

- Leverage the advantages of GACP-compliant medicinal herb cultivation areas to develop and manufacture products for therapeutic use and export markets.

3. Market and Marketing Strategy

- Strengthen and expand the existing distribution network.

- Focus on developing the customer network in the Central and Southern provinces.

- Expand the export customer base in order to optimize production capacity and improve the Company's operational efficiency.

- Promote marketing activities and strengthen brand building.

The goal is to improve marketing effectiveness (customer reach, content personalization, budget optimization, advertising) while simultaneously supporting sales (lead management, demand prediction) in a thorough and easily implementable way.

- Sales support: strengthen customer management and demand forecasting, while enhancing the customer experience and increasing customer loyalty to the Company's products and services.

4. Financial and Governance Strategy

- Continue implementing solutions to apply specialized software and promote digital transformation in management activities.

- Strengthen strict control over costs: enhance business efficiency through solutions that clearly define performance outcomes and implement effective risk prevention and control measures.

5. Invest deeply in research and development to create products with high scientific and technological value and strong therapeutic effectiveness, contributing to the protection and improvement of public health.

Distinguished delegates, honored guests, and respected shareholders!

Today, 7 April 2026, we convene the 6th Annual General Meeting of Shareholders for 2026 in this formal and distinguished hall. Entering a new year, we have every reason to take pride in what the Company has achieved. The Company continues to move forward steadily, delivering increasing benefits to shareholders, contributing to the rapid development of Vietnam's pharmaceutical industry, ensuring employment, improving the livelihoods of our employees, and fully fulfilling tax obligations to contribute to the State budget. Hai Duong Pharmaceutical Medical Materials Joint Stock Company is determined to develop the HDPHARMA

brand into a strong and reputable brand, as well as a desirable workplace for talented young professionals and dedicated employees. The achievements we have attained serve as a solid foundation and a strong source of confidence for accomplishing the goals and plans set for this year and the subsequent development stages by the Company's leadership and by all of us—our shareholders. This report also serves as an important basis for the Company's shareholders and investors to carefully consider and exercise their voting rights at this Meeting in order to approve the resolutions concerning economic and financial objectives, as well as investment and development policies for the 2026 financial year. The Company's leadership sincerely appreciates the intellectual contributions and financial support of our shareholders and investors, which are essential for successfully implementing the Company's production and business objectives for 2026.

Although many challenges remain, we firmly believe that with the right direction, sound strategies, and appropriate policies, together with our ability to seize opportunities, mobilize all available resources, and work efficiently, we will overcome every difficulty and challenge, achieve our strategic objectives, and move confidently toward success.

I wish the General Meeting great success, and extend my best wishes to our distinguished delegates, honored guests, esteemed shareholders, and all participants of the Annual General Meeting of Hai Duong Pharmaceutical Medical Materials Joint Stock Company for good health, happiness, and continued success in the year ahead.


Recipients:

- The Company's Shareholders;
- Board of Directors and Supervisory Board;
- Saved at the Office.

**ON BEHALF OF THE BOARD OF
MANAGEMENT
GENERAL DIRECTOR**



Nguyen Thi Tu Anh



Số/No.: 01/Ttr – HĐQT

TỜ TRÌNH SỐ 01

V/v Thông qua Báo cáo hoạt động của HĐQT, BKS năm 2025; Báo cáo hoạt động SX - KD năm 2025 và kế hoạch SX – KD năm 2026

PROPOSAL NO. 01

Re: Approval of the 2025 Activity Report of the Board of Directors and the Supervisory Board; the 2025 Business Operations Report and the 2026 Business Plan.

Kính gửi: Đại hội đồng cổ đông Công ty Cổ phần Dược Vật tư y tế Hải Dương

To: The General Meeting of Shareholders of Hai Duong Pharmaceutical Medical Materials Joint Stock Company

- Căn cứ Luật Doanh nghiệp số 59/2020/QH14 ngày 17/6/2020;
- Căn cứ vào Điều lệ Công ty Cổ phần Dược Vật tư y tế Hải Dương được Đại hội đồng cổ đông thường niên năm 2025 thông qua ngày 03/04/2025;
- Pursuant to the Enterprise Law No. 59/2020/QH14 dated June 17, 2020;
- Pursuant to the Charter of Hai Duong Pharmaceutical Medical Materials Joint Stock Company as approved by the Annual General Meeting of Shareholders on April 3, 2025.

Hội đồng quản trị kính trình Đại hội đồng cổ đông công ty xem xét thông qua nội dung sau:

- Báo cáo hoạt động của Hội đồng quản trị năm 2025;
- Báo cáo hoạt động Sản xuất kinh doanh năm 2025 và kế hoạch năm 2026;
- Báo cáo hoạt động của Ban Kiểm soát năm 2025.

The Board of Directors respectfully submits to the General Meeting of Shareholders for consideration and approval of the following matters:

- *The 2025 Activity Report of the Board of Directors;*
- *The 2025 Business Operations Report and the 2026 Business Plan;*
- *The 2025 Activity Report of the Supervisory Board.*



Kính trình Đại hội đồng cổ đông công ty xem xét thông qua.

Xin trân trọng cảm ơn!

Respectfully submitted to the General Meeting of Shareholders for consideration and approval.

*Sincerely,
Thank you!*

Nơi nhận/Recipients:

- Như trên/As stated above;
- HĐQT, Ban GD, Ban KS/
Board of Directors, Executive Board, Supervisory Board,;
- Lưu TC-HC, TCKT.
To be archived by:
Administration & Human Resources Dept, Finance & Accounting Dept.

TM. HỘI ĐỒNG QUẢN TRỊ
CHỦ TỊCH

ON BEHALF OF
BOARD OF DIRECTORS
CHAIRMAN



CHỦ TỊCH HĐQT
NGUYỄN TRUNG VIỆT



Số/No.: 02/Ttr – HĐQT

TỜ TRÌNH SỐ 02

V/v Thông qua Báo cáo tài chính năm 2025 đã được kiểm toán

PROPOSAL NO. 02

Re: Approval of the Audited 2025 Financial Statements

Kính gửi: Đại hội đồng cổ đông Công ty Cổ phần Dược Vật tư y tế Hải Dương

To: The General Meeting of Shareholders of Hai Duong Pharmaceutical Medical Materials Joint Stock Company

- Căn cứ Luật Doanh nghiệp số 59/2020/QH14 ngày 17/6/2020;
- Căn cứ vào Điều lệ Công ty Cổ phần Dược Vật tư y tế Hải Dương được Đại hội đồng cổ đông thường niên năm 2025 thông qua ngày 03/04/2025,
- Pursuant to the Enterprise Law No. 59/2020/QH14 dated June 17, 2020;
- Pursuant to the Charter of Hai Duong Pharmaceutical and Medical Equipment Joint Stock Company, as approved by the 2025 Annual General Meeting of Shareholders on April 3, 2025.

Hội đồng quản trị kính trình Đại hội đồng cổ đông công ty xem xét thông qua Báo cáo tài chính năm 2025 đã được Chi nhánh Công ty TNHH kiểm toán và Thẩm định giá Việt Nam tiến hành kiểm toán tuân theo các Chuẩn mực kế toán Việt Nam, được Ban kiểm soát Công ty kiểm tra và đã được Hội đồng quản trị CTCP Dược Vật tư y tế Hải Dương công bố công khai theo quy định. Các Báo cáo tài chính năm 2025 đã được kiểm toán bao gồm:

The Board of Directors respectfully submits to the General Meeting of Shareholders for consideration and approval of the 2025 Financial Statements, which have been audited by Vietnam Auditing and Valuation Company Limited (Branch) in compliance with Vietnamese Accounting Standards. These financial statements have been reviewed by the Supervisory Board and publicly disclosed by the Board of Directors as required.

- (1) Báo cáo của Ban Giám đốc
- (2) Báo cáo của Kiểm toán viên
- (3) Bảng Cân đối kế toán tại ngày 31/12/2025
- (4) Báo cáo Kết quả hoạt động kinh doanh năm 2025
- (5) Báo cáo Lưu chuyển tiền tệ năm 2025
- (6) Thuyết minh Báo cáo tài chính năm 2025

The audited 2024 financial statements include:

- (1) Report of the Executive Board
- (2) Report of the Auditor
- (3) Balance Sheet as of December 31, 2025
- (4) Income Statement for 2025
- (5) Cash Flow Statement for 2025
- (6) Notes to the Financial Statements for 2025

Trong đó, có một số chỉ tiêu cơ bản:

Where, a number of major indicators are presented:

BÁO CÁO TÀI CHÍNH TÓM TẮT
SUMMARY OF FINANCIAL STATEMENTS

ĐVT: Đồng
Unit: VND

Tên chỉ tiêu <i>Indicators</i>	Số dư cuối năm <i>Year-end balance</i>	Số dư đầu năm <i>Beginning balance</i>
A - TÀI SẢN NGẮN HẠN <i>CURRENT ASSETS</i>	333.086.878.632 <i>333,086,878,632</i>	341.148.607.589 <i>341,148,607,589</i>
1. Tiền và các khoản tương đương tiền <i>Cash and cash equivalents</i>	44.408.946.125 <i>44,408,946,125</i>	31.419.168.182 <i>31,419,168,182</i>
2. Các khoản phải thu ngắn hạn <i>Short-term receivables</i>	121.037.997.415 <i>121,037,997,415</i>	180.755.628.545 <i>180,755,628,545</i>
3. Hàng tồn kho <i>Inventories</i>	143.634.151.611 <i>143,634,151,611</i>	127.909.053.084 <i>127,909,053,084</i>
4. Tài sản ngắn hạn khác <i>Other current assets</i>	24.005.783.481 <i>24,005,783,481</i>	1.064.757.778 <i>1,064,757,778</i>
B TÀI SẢN DÀI HẠN <i>NON-CURRENT ASSETS</i>	619.463.353.172 <i>619,463,353,172</i>	305.237.748.766 <i>305,237,748,766</i>
1.1. Tài sản cố định hữu hình	471.482.526.434	259.687.221.789

<i>Tangible fixed assets</i>	471,482,526,434	259,687,221,789
- Nguyên giá	696.766.214.346	481.416.768.768
<i>Original cost</i>	696,766,214,346	481,416,768,768
- Giá trị hao mòn lũy kế (*)	(243.535.038.268)	(221.729.546.979)
<i>Accumulated depreciation value (*)</i>	(243,535,038,268)	(221,729,546,979)
1.2. Tài sản cố định vô hình	18.251.350.356	18.251.350.356
<i>Intangible fixed assets</i>	18,251,350,356	18,251,350,356
- Nguyên giá	25.557.287.846	25.557.287.846
<i>Original cost</i>	25,557,287,846	25,557,287,846
- Giá trị hao mòn lũy kế (*)	(7.305.937.490)	(7.305.937.490)
<i>Accumulated depreciation value (*)</i>	(7,305,937,490)	(7,305,937,490)
1.3. Chi phí xây dựng cơ bản dở dang	142.391.317.925	24.432.507.459
<i>Construction in progress (CIP) cost</i>	142,391,317,925	24,432,507,459
2. Các khoản đầu tư tài chính dài hạn	1.835.000.000	0
<i>Long-term financial investments</i>	1,835,000,000	0
3. Tài sản dài hạn khác	3.754.508.813	2.866.669.162
<i>Other non-current assets</i>	3,754,508,813	2,866,669,162
TỔNG TÀI SẢN	952.550.231.804	646.386.356.355
TOTAL ASSETS	952,550,231,804	646,386,356,355
C - NỢ PHẢI TRẢ	449.236.682.497	192.127.190.710
LIABILITIES	449,236,682,497	192,127,190,710
1. Phải trả người bán	74.933.027.107	63.913.046.095
<i>Accounts payable to suppliers</i>	74,933,027,107	63,913,046,095

2. Người mua trả tiền trước <i>Advances from customers</i>	28.319.984.253 28,319,984,253	27.011.433.156 27,011,433,156
3. Thuế và các khoản phải nộp Nhà nước <i>Taxes and payables to the government</i>	10.009.726.250 10,009,726,250	7.152.037.955 7,152,037,955
4. Phải trả người lao động <i>Payables to employees</i>	16.953.397.272 16,953,397,272	4.869.401.998 4,869,401,998
5. Chi phí phải trả ngắn hạn <i>Short-term accrued expenses</i>	602.366.762 602,366,762	428.162.066 428,162,066
6. Doanh thu chưa thực hiện ngắn hạn <i>Short-term unearned revenue</i>	1.000.537.013 1,000,537,013	3.201.934.270 3,201,934,270
7. Phải trả ngắn hạn khác <i>Other short-term payables</i>	7.550.378.347 7,550,378,347	7.182.181.347 7,182,181,347
8. Vay và nợ thuê tài chính ngắn hạn <i>Short-term borrowings and finance lease liabilities</i>	66.805.817.846 66,805,817,846	65.925.328.072 65,925,328,072
9. Quỹ khen thưởng phúc lợi <i>Bonus and welfare fund</i>	6.007.170.790 6,007,170,790	6.428.370.790 6,428,370,790
II Nợ dài hạn <i>Long-term liabilities</i>	237.054.276.857 237,054,276,857	6.018.294.961 6,018,294,961
1. Vay và nợ thuê tài chính dài hạn <i>Long-term borrowings and finance lease liabilities</i>	217.048.292.142 217,048,292,142	6.002.713.990 6,002,713,990
2. Quỹ phát triển khoa học và công nghệ <i>Science and technology development fund</i>	5.987.715 5,987,715	15.580.971 15,580,971

D - VỐN CHỦ SỞ HỮU	503.313.549.307	454.259.165.645
OWNER'S EQUITY	503,313,549,307	454,259,165,645
1. Vốn góp của chủ sở hữu	359.959.290.000	279.473.190.000
<i>Owner's contributed capital</i>	<i>359,959,290,000</i>	<i>249,473,190,000</i>
2. Quỹ đầu tư phát triển	79.594.214.888	124.594.214.888
<i>Development investment fund</i>	<i>79,594,214,888</i>	<i>124,594,214,888</i>
3. Lợi nhuận sau thuế chưa phân phối	63.760.044.419	50.191.780.757
<i>Undistributed after-tax profit</i>	<i>63,760,044,419</i>	<i>50,191,780,757</i>
+ Lợi nhuận sau thuế chưa phân phối năm trước	8.425.031.277	9.870.172.861
<i>Undistributed after-tax profit of previous years</i>	<i>8,425,031,277</i>	<i>9,870,172,861</i>
+ Lợi nhuận sau thuế chưa phân phối năm nay	55.335.013.142	40.321.607.896
<i>Undistributed after-tax profit of the current year</i>	<i>55,335,013,142</i>	<i>40,321,607,896</i>
TỔNG NGUỒN VỐN	952.550.231.804	646.386.356.355
TOTAL CAPITAL RESOURCES	952,550,231,804	646,386,356,355

BÁO CÁO KẾT QUẢ HOẠT ĐỘNG SẢN XUẤT KINH DOANH
INCOME STATEMENT (STATEMENT OF BUSINESS PERFORMANCE)

DVT: Đồng
Unit: VND

STT NO	CHỈ TIÊU INDICATOR	NĂM 2025	NĂM 2024
1	Doanh thu bán hàng hóa, dịch vụ <i>Revenue from sales of goods and services</i>	689.532.822.613 <i>689,532,822,613</i>	668.056.188.242 <i>668,056,188,242</i>
2	Các khoản giảm trừ doanh thu <i>Deductions from revenue</i>	5.819.302.260 <i>5,819,302,260</i>	3.084.479.448 <i>3,084,479,448</i>
3	Doanh thu thuần	683.713.520.353	665.001.708.794

STT NO	CHỈ TIÊU INDICATOR	NĂM 2025	NĂM 2024
	<i>Net revenue</i>	683,713,520,353	665,001,708,794
4	Giá vốn hàng bán <i>Cost of goods sold</i>	438.734.362.525 438,,734,362,525	484.770.265.987 484,770,265,987
5	Lợi nhuận gộp bán HHóa và dịch vụ <i>Gross profit from sales of goods and services</i>	244.979.154.828 244,979,154,828	210.231.442.807 210,231,442,807
6	Doanh thu từ hoạt động tài chính <i>Financial income</i>	1.217.152.638 1,217,152,638	633.188.787 633,188,787
7	Chi phí tài chính <i>Financial expenses</i>	5.681.886.282 5,681,886,282	6.255.488.148 6,255,488,148
8	Chi phí bán hàng <i>Selling expenses</i>	79.028.832.449 79,028,832,449	74.149.536.551 74,149,536,551
9	Chi phí quản lý doanh nghiệp <i>General and administrative expenses</i>	93.156.777.114 93,156,777,114	81.814.791.647 81,814,791,647
10	Lợi nhuận thuần từ hoạt động SX- KD <i>Net profit from business activities</i>	68.328.814.621 68,328,814,621	48.644.815.248 48,644,815,248
11	Thu nhập khác <i>Other income</i>	1.983.041.896 1,983,041,896	2.152.468.731 2,152,468,731
12	Chi phí khác <i>Other expenses</i>	546.295.012 546,295,012	8.775.306 8,775,306
13	Lợi nhuận khác <i>Other profit</i>	1.436.746.884 1,436,746,884	2.143.693.425 2,143,693,425

STT NO	CHỈ TIÊU INDICATOR	NĂM 2025	NĂM 2024
14	Tổng lợi nhuận kế toán trước thuế <i>Total accounting profit before tax</i>	69.765.561.505 <i>69,765,561,505</i>	50.788.508.673 <i>50,788,508,673</i>
15	Chi phí thuế thu nhập doanh nghiệp <i>Corporate income tax expense</i>	14.062.371.303 <i>14,062,371,303</i>	10.179.727.977 <i>10,179,727,977</i>
16	Lợi nhuận sau thuế thu nhập DN <i>Net profit after corporate income tax</i>	55.703.190.202 <i>55,703,190,202</i>	40.608.780.696 <i>40,608,780,696</i>
17	Lãi cơ bản/ 01 cổ phiếu <i>Basic earnings per share</i>	1.548 <i>1,548</i>	1.128 <i>1,128</i>

Năm 2025, Công ty đã tăng vốn điều lệ từ thặng dư vốn cổ phần và lợi nhuận sau thuế chưa phân phối. Vì vậy lãi cơ bản trên cổ phiếu cùng kỳ năm trước đã được điều chỉnh lại theo số cổ phiếu phát hành thêm. Việc điều chỉnh hồi tố theo chuẩn mực kế toán Việt Nam làm cho lãi cơ bản trên cổ phiếu năm trước giảm từ: 1.453 đồng/ cổ phiếu xuống còn: 1.128 đồng/ cổ phiếu.

In 2025, the company increased its charter capital from share premium and undistributed after-tax profit. As a result, the basic earnings per share (EPS) of the same period last year were adjusted to reflect the additional issued shares. The retrospective adjustment, in accordance with Vietnamese accounting standards, reduced the previous year's basic EPS from 1,453 VND per share to 1,128 VND per share.

Kính trình Đại hội đồng cổ đông công ty xem xét thông qua.

Xin trân trọng cảm ơn!

Respectfully submitted to the General Meeting of Shareholders for consideration and approval.

Sincerely,

Nơi nhận/Recipients:

- Như trên/As stated above;
- HĐQT, Ban GD, Ban KS/
*Board of Directors, Executive Board,
Supervisory Board;*
- Lưu TC-HC, TCKT.
*To be archived by: Administration & Human
Resources Dept, Finance & Accounting
Dept.*

TM. HỘI ĐỒNG QUẢN TRỊ
CHỦ TỊCH
ON BEHALF OF
BOARD OF DIRECTORS
CHAIRMAN



CHỦ TỊCH HĐQT
NGUYỄN TRUNG VIỆT



Số/No.: 03/Ttr – HĐQT

TỜ TRÌNH SỐ 03

**V/v: Thông qua Phương án phân phối lợi nhuận năm 2025
và dự toán tài chính năm 2026**

PROPOSAL NO. 03

**Re: Approval of the 2025 Profit Distribution Plan and the 2026 Financial
Budget**

Kính gửi: Đại hội đồng cổ đông Công ty Cổ phần Dược Vật tư y tế Hải Dương

*To: The General Meeting of Shareholders of Hai Duong Pharmaceutical Medical
Materials Joint Stock Company*

- Căn cứ Luật Doanh nghiệp số 59/2020/QH14 ngày 17/6/2020 đã được Quốc hội Nước Cộng Hòa Xã hội Chủ Nghĩa Việt Nam thông qua, sửa đổi bởi Luật số 03/2022/QH15 được Quốc hội thông qua ngày 11/01/2022 và Luật số 76/2025/QH15 được Quốc hội thông qua ngày 17/06/2025 và các văn bản hướng dẫn thi hành;
- Căn cứ vào Điều lệ tổ chức và hoạt động của Công ty Cổ phần Dược Vật tư y tế Hải Dương được Đại hội đồng cổ đông thường niên năm 2025 thông qua ngày 03/04/2025;
- Căn cứ vào kết quả SX - KD của Công Ty CP Dược Vật tư y tế Hải Dương trong năm 2025 và quy định về tỷ lệ trích lập các quỹ theo Điều lệ Công ty,
- *Pursuant to the Law on Enterprises No. 59/2020/QH14 dated June 17, 2020, passed by the National Assembly of the Socialist Republic of Vietnam, amended by Law No. 03/2022/QH15, passed by the National Assembly of the Socialist Republic of Vietnam on January 11, 2022, and Law No. 76/2025/QH15, passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2025, and its implementing guidance documents;*
- *Pursuant to the Charter on the organization and operation of Hai Duong Pharmaceutical Medical Materials Joint Stock Company, as approved by the Annual General Meeting of Shareholders in 2025 on April 3, 2025;*
- *Pursuant to the business performance results of Hai Duong Pharmaceutical Medical Materials Joint Stock Company in 2025 and the provisions on the allocation ratio of funds as stipulated in the Company's Charter.*

Hội đồng quản trị kính trình Đại hội đồng cổ đông công ty xem xét thông qua Phương án phân phối lợi nhuận năm 2025 và kế hoạch năm 2026, như sau:

The Board of Directors respectfully submits to the General Meeting of Shareholders for consideration and approval the 2025 Profit Distribution Plan and the 2026 Financial Plan, as follows:

1. Phương án phân phối lợi nhuận năm tài chính 2025 và lợi nhuận năm trước chuyển sang.

Profit Distribution Plan for the Fiscal Year 2025 and Retained Earnings from Previous Years

STT No	Chỉ tiêu Indicators	Số tiền (đồng) Amount (VND)
1	Lợi nhuận năm trước chưa phân phối chuyển sang <i>Undistributed Profit Carried Forward from Previous Years</i>	8.425.031.277 8,425,031,277
2	Tổng lợi nhuận sau thuế thu nhập doanh nghiệp năm 2025 <i>Total After-Tax Profit for the Year 2025</i>	55.703.190.202 55,703,190,202
3	Trả cổ tức năm 2025 Tỷ lệ là: 1,8% . <u>Hình thức</u> : - Trả bằng tiền 1,8% : 6.479.267.220 đ <i>Dividend Payment for 2025, rate: 1.8%</i> <u>Form of Payment:</u> <i>Cash payment at 1.8%: 6,479,267,220 VND</i>	6.479.267.220 6,479,267,220
4	Trả thù lao cho thành viên HĐQT, BKS không tham gia điều hành năm 2025 quyết toán theo Điều lệ <i>Remuneration Payment for Non-Executive Members of the Board of Directors (BOD) and the Board of Supervisors (BOS) in 2025, settlement in accordance with the Company's Charter</i>	557.215.200 557.215.200
5	Tổng lợi nhuận còn lại chưa phân phối <i>Total Remaining Undistributed Profit</i> (5=1+2-3-4)	57.091.739.059 57,091,739,059
6	Phát hành cổ phiếu để tăng vốn cổ phần từ nguồn vốn chủ sở hữu <i>Issuing Shares to Increase Charter Capital from Owner's Equity</i>	Tối đa 46.391.535.112 Up to 46,391,535,112

7	<p>Tổng lợi nhuận chưa phân phối còn lại chuyển sang năm sau, chưa phân phối cho cổ đông</p> <p><i>Total Undistributed Profit Carried Forward to the Next Year, not yet distributed to shareholders</i></p>
---	---

Công ty sẽ thực hiện trả cổ tức năm 2025 bằng tiền cho các cổ đông theo nghị quyết của Đại hội đồng cổ đông năm 2026 đề ra, số tiền là: 6.479.267.220 đồng, từ nguồn lợi nhuận chưa phân phối năm 2025 và năm trước chuyển sang, có trên báo cáo tài chính lập ngày 31/12/2025 đã được kiểm toán, tương đương với tỷ lệ là: 1,8% (01 cổ phiếu được nhận 180 đồng).

The company will distribute the 2025 dividends in cash to shareholders in accordance with the resolution of the 2026 General Meeting of Shareholders. The total amount to be distributed is 6,479,267,220 VND, sourced from undistributed profits from 2025 and previous years, as recorded in the audited financial statements as of December 31, 2025. This corresponds to a dividend rate of 1.8%, which means each share will receive 180 VND.

2. Dự toán tài chính năm 2026

Financial Budget for 2026

- Giá trị sản lượng sản xuất: **518** tỷ đồng, trong đó:

Production Output Value: 518 billion VND, including:

TT No	Tên đơn vị <i>Production line</i>	Đơn vị tính <i>Unit</i>	Chỉ tiêu Giao <i>Assigned target</i>
1	Phân xưởng Cao nước <i>Herbal extract</i>	Tỷ đồng <i>Billion</i>	40 40
2	Phân xưởng Kem mỡ nước, mỹ phẩm <i>Cream, ointment, solution, cosmetic</i>	Tỷ đồng <i>Billion</i>	22,5 22.5
3	Phân xưởng Nang mềm <i>Softgel</i>	Tỷ đồng <i>Billion</i>	106 106
4	Phân xưởng Tiêm Tra mắt <i>Injectables, ophthalmic</i>	Tỷ đồng <i>Billion</i>	115 115
5	Phân xưởng Viên (Nhà máy tại 102 Chi Lăng) <i>OSD (102 Chi Lang Plant)</i>	Tỷ đồng <i>Billion</i>	90 90

TT No	Tên đơn vị <i>Production line</i>	Đơn vị tính <i>Unit</i>	Chỉ tiêu Giao <i>Assigned target</i>
6	Phân xưởng Viên 1 - EU OSD line 1 – EU	Tỷ đồng <i>Billion</i>	100 100
7	Phân xưởng Viên 2 – WHO OSD line 2 – WHO	Tỷ đồng <i>Billion</i>	27,5 27.5
8	Phân xưởng Ống uống (<i>Thủy tinh</i>) <i>Oral solution in glass ampoules</i>	Tỷ đồng <i>Billion</i>	17 17
	CỘNG TOTAL		518 518

- Doanh thu: **840** tỷ đồng, Gồm doanh thu nội bộ: **10** tỷ đồng và Doanh thu bán cho khách hàng: **830** tỷ đồng

Trong đó :

- + *Doanh thu hàng kinh doanh thương mại: 249 tỷ đồng, chiếm 30%*
- + *Doanh thu hàng công ty sản xuất: 581 tỷ đồng, chiếm 70%*

- Lãi gộp: 230 tỷ đồng

- Dự kiến lợi nhuận sau thuế là: 45.000.000.000 đồng.

- *Revenue: 840 billion VND, including, internal revenue: 10 billion VND, revenue from sales to customers: 830 billion VND*

Breakdown:

+ *Revenue from trading goods: 249 billion VND (30%)*

+ *Revenue from company-manufactured products: 581 billion VND (70%)*

- *Gross profit: 230 billion VND*

- *Projected after-tax profit: 45,000,000,000 VND (45 billion VND).*

- Dự kiến phân phối lợi nhuận sau thuế của năm 2026:

- + *Trích lập vào quỹ đầu tư phát triển theo điều lệ công ty và nghị quyết đại hội đồng cổ đông.*
- + *Trả cổ tức bằng tiền cho các cổ đông dự kiến mức từ 2% đến 6%.*

- Projected Distribution of After-Tax Profit for 2026:

- + *Allocation to the Development Investment Fund in accordance with the company's charter and the resolution of the General Meeting of Shareholders.*

+ *Dividend payment to shareholders in the form of cash, with an expected rate ranging from 2% to 6%.*

Trên đây là nội dung phương án phân phối lợi nhuận năm tài chính 2025 và kế hoạch lợi nhuận và phân phối lợi nhuận cho năm tài chính 2026, kính trình Đại hội đồng cổ đông thường niên 2026 xem xét thông qua.
Xin trân trọng cảm ơn!

The above outlines the profit distribution plan for the fiscal year 2025 and the profit plan and distribution for the fiscal year 2026. Respectfully submitted to the 2026 Annual General Meeting of Shareholders for consideration and approval.

Sincerely,

Nơi nhận/Recipients:

- Như trên/As stated above;
- HĐQT, Ban GD, Ban KS/
Board of Directors, Board of Management, Board of Supervisors;
- Lưu TC-HC, TCKT.
To be archived by:
Administration & Human Resources Dept, Finance & Accounting Dept.

TM. HỘI ĐỒNG QUẢN TRỊ
CHỦ TỊCH
ON BEHALF OF BOARD OF DIRECTORS
CHAIRMAN



CHỦ TỊCH HĐQT
NGUYỄN TRUNG VIỆT

Số/No.: 04/Ttr – HĐQT

TỜ TRÌNH SỐ 04

**V/v Thông qua chi trả thù lao cho HĐQT, BKS năm 2025 và đề xuất năm 2026
PROPOSAL NO. 04**

**Regarding the Approval of Remuneration for the Board of Directors (BOD)
and Supervisory Board (SB) for 2025 and Proposal for 2026**

Kính gửi: Đại hội đồng cổ đông Công ty Cổ phần Dược Vật tư y tế Hải Dương

**To: The General Meeting of Shareholders of Hai Duong Pharmaceutical Medical
Materials Joint Stock Company**

- Căn cứ Luật Doanh nghiệp số 59/2020/QH14 ngày 17/6/2020;
- Căn cứ vào Điều lệ Công ty Cổ phần Dược Vật tư y tế Hải Dương được Đại hội đồng cổ đông thường niên năm 2025 thông qua ngày 03/04/2025;
- Căn cứ vào kết quả SXKD của Công Ty Cổ Phần Dược Vật tư y tế Hải Dương trong năm 2025 đã được kiểm toán.
- Pursuant to the Law on Enterprises No. 59/2020/QH14 dated June 17, 2020;
- Pursuant to the Charter of Hai Duong Pharmaceutical Medical Materials Joint Stock Company approved by the Annual General Meeting of Shareholders on April 3, 2025;
- Pursuant to the audited business performance results of Hai Duong Pharmaceutical Medical Materials Joint Stock Company for the year 2025.

Hội đồng quản trị kính trình Đại hội đồng cổ đông công ty xem xét thông qua quyết toán chi trả thù lao cho HĐQT, BKS năm 2025 và đề xuất năm 2026, như sau:

The Board of Directors respectfully submits to the General Meeting of Shareholders for consideration and approval the finalization of remuneration payments for the Board of Directors and the Supervisory Board in 2025, along with the proposal for 2026, as follows:

1. Thù lao HĐQT, BKS theo điều lệ quyết toán trong năm 2025

Remuneration for the Board of Directors and the Supervisory Board finalized in 2025 as stipulated in the Company Charter.

- Số lượng thành viên Hội đồng quản trị năm 2025 là 3 thành viên
- Số lượng thành viên Ban kiểm soát năm 2025 là 3 thành viên
- Tổng số lợi nhuận sau thuế thu nhập doanh nghiệp: 55.703.190.202 đồng
- Thù lao cho HĐQT là: 1.671.645.600 đồng; Tương đương 3% lợi nhuận sau thuế năm 2025. Cụ thể:

- *Number of members of the Board of Directors in 2025: 3 members*
- *Number of members of the Supervisory Board in 2025: 3 members*
- *Total profit after corporate income tax: VND 55,703,190,202*
- *Remuneration for the Board of Directors: VND 1,671,645,600, equivalent to 3% of the after-tax profit for 2025, detailed as follows:*

STT No	Họ và tên Name	Chức vụ Position	Thù lao năm 2025 (đồng) Remuneration for 2025 (VND)
1	Ông Nguyễn Trung Việt Mr Nguyen Trung Viet	Chủ tịch HĐQT Chairman of the Board	557.215.200 557,215,200
2	Bà Nguyễn Thị Tú Anh Mrs Nguyen Thi Tu Anh	Thành viên HĐQT- TGD Member of the Board- General Director	557.215.200 557,215,200
3	Ông Trần Phúc Dương Mr Tran Phuc Duong	Thành viên HĐQT không tham gia điều hành Non-executive Member of the Board of Directors	557.215.200 557,215,200
	Cộng Total		1.671,645,600 1,671,645,600

- Thù lao cho BKS là: 557.215.200 đồng; Tương đương 1% lợi nhuận sau thuế năm 2025. Cụ thể:

Remuneration for the Supervisory Board: VND 557,215,200, equivalent to 1% of the after-tax profit for 2025, detailed as follows:

STT No	Họ và tên Name	Chức vụ Position	Thù lao năm 2025 (đồng) Remuneration for 2025 (VND)
1	Bà Phạm Thị Thủy <i>Mrs Phạm Thị Thủy</i>	Trưởng Ban Kiểm Soát <i>Head of the Supervisory Board</i>	185.738.400 <i>185,738,400</i>
2	Bà Nguyễn Thị Hương Lan <i>Mrs Nguyễn Thị Hương Lan</i>	Thành viên BKS <i>Member of the Supervisory Board</i>	185.738.400 <i>185,738,400</i>
3	Ông Trần Kim Cương <i>Mr Tran Kim Cuong</i>	Thành viên BKS <i>Member of the Supervisory Board</i>	185.738.400 <i>185,738,400</i>
	Cộng Total		557.215.200 557,215,200

Như vậy khoản chi thù lao HĐQT và BKS năm 2025 đã thực hiện đúng định mức chi trả theo Điều lệ công ty.

Thus, the remuneration payments to the Board of Directors and the Supervisory Board for 2025 have complied with the limits stipulated in the Company Charter.

2. Mức thù lao dự kiến chi trả trong năm 2026

Proposed remuneration for 2025

Căn cứ vào điều lệ công ty đã được đại hội thông qua và kết quả kinh doanh của năm 2025.

- Thù lao cho HĐQT là 3% lợi nhuận sau thuế thu nhập doanh nghiệp
- Thù lao cho BKS là 1% lợi nhuận sau thuế thu nhập doanh nghiệp

Based on the Company Charter approved by the General Meeting and the business performance results of 2025:

- *Remuneration for the Board of Directors is 3% of after-tax profit.*
- *Remuneration for the Supervisory Board is 1% of after-tax profit.*

Trên đây là nội dung kết quả chi trả thù lao cho HĐQT, BKS năm 2025 và kế hoạch thù lao năm 2026, kính trình Đại hội đồng cổ đông thường niên 2026 xem xét và phê duyệt.

The above content outlines the remuneration payments made to the Board of Directors and the Supervisory Board for 2025, along with the proposed remuneration plan for 2026, respectfully submitted to the Annual General Meeting of Shareholders 2026 for consideration and approval.

Xin trân trọng cảm ơn!

Sincerely thank you!

Nơi nhận/Recipients:

- Như trên/As stated above;
- HĐQT, Ban GD, Ban KS/
Board of Directors, Executive Board,
Supervisory Board,;
- Lưu TC-HC, TCKT.
To be archived by: Administration & Human
Resources Dept, Finance & Accounting Dept

TM. HỘI ĐỒNG QUẢN TRỊ
CHỦ TỊCH
ON BEHALF OF
BOARD OF DIRECTORS
CHAIRMAN



CHỦ TỊCH HĐQT
NGUYỄN TRUNG VIỆT

Số/No.: 05/Ttr – HĐQT

TỜ TRÌNH SỐ 05

V/v Thông qua việc lựa chọn đơn vị kiểm toán BCTC năm 2026
PROPOSAL NO. 05

Re: Approval of the selection of an audit firm for the 2026 financial statements

Kính gửi: Đại hội đồng cổ đông Công ty Cổ phần Dược Vật tư y tế Hải Dương
To: The General Meeting of Shareholders of Hai Duong Pharmaceutical Medical Materials Joint Stock Company

- Căn cứ Luật Doanh nghiệp số 59/2020/QH14 ngày 17/6/2020;
- Căn cứ vào Điều lệ Công ty Cổ phần Dược Vật tư y tế Hải Dương được Đại hội đồng cổ đông thường niên năm 2025 thông qua ngày 03/4/2025;
- Căn cứ vào tình hình thực tế của Công ty,
- Pursuant to the Law on Enterprises No. 59/2020/QH14 dated June 17, 2020;
- Pursuant to the Charter of Hai Duong Pharmaceutical and Medical Materials Joint Stock Company, approved by the Annual General Meeting of Shareholders on April 3, 2025;
- Based on the actual situation of the Company,

Hội đồng Quản trị kính trình Đại hội đồng cổ đông công ty xem xét thông qua về việc lựa chọn đơn vị kiểm toán BCTC năm 2026 như sau:

The Board of Directors respectfully submits to the General Meeting of Shareholders for consideration and approval of the selection of an audit firm for the 2026 financial statements, as follows:

1. Tiêu thức lựa chọn

Selection criteria

- Là đơn vị kiểm toán độc lập có uy tín, được UBCKNN và Bộ Tài chính chấp thuận kiểm toán cho các các công ty đại chúng;

- Là đơn vị kiểm toán có đội ngũ kiểm toán viên trung thực, đề cao đạo đức nghề nghiệp, có trình độ cao, nhiều kinh nghiệm nhằm đảm bảo chất lượng kiểm toán báo cáo tài chính;
- Chi phí kiểm toán hợp lý, phù hợp với nội dung, phạm vi và tiến độ kiểm toán do Công ty yêu cầu.
- *Must be a reputable independent audit firm approved by the State Securities Commission (SSC) and the Ministry of Finance to audit public companies.*
- *Must have a team of auditors who are honest, uphold professional ethics, highly qualified, and experienced to ensure high-quality financial statement audits.*
- *Audit fees should be reasonable and aligned with the audit scope, content, and timeline required by the Company.*

2. Danh sách một số đơn vị kiểm toán

List of some audit firms

- Chi nhánh công ty TNHH kiểm toán và dịch vụ tin học MOORE AISC;
- Công ty TNHH kiểm toán An Việt;
- Công ty TNHH KPMG;
- Công ty TNHH kiểm toán và thẩm định giá Việt Nam;

Hoặc các đơn vị kiểm toán đủ điều kiện khác tại thời điểm công ty có nhu cầu lựa chọn.

- *Moore AISC Auditing and Informatics Services Company Limited – Branch Office;*
- *An Viet Auditing Company Limited;*
- *KPMG Company Limited;*
- *Vietnam Auditing and Valuation Company Limited.*

Or other qualified auditing firms available at the time when the selection is needed.

Hội đồng quản trị xin kính trình Đại hội đồng cổ đông chấp thuận ủy quyền cho Hội đồng quản trị trực tiếp chọn một đơn vị kiểm toán phù hợp, đáp ứng được những yêu cầu trên để kiểm toán Báo cáo tài chính năm 2026 của Công ty.

The Board of Directors respectfully submits to the General Meeting of Shareholders for approval of the authorization of the Board of Directors to directly select an audit firm that satisfies the above criteria to perform the audit of the Company's 2026 financial statements.

Kính trình Đại hội đồng cổ đông công ty xem xét thông qua.

Xin trân trọng cảm ơn!

Respectfully submitted to the General Meeting of Shareholders for consideration and approval.

Sincerely thanks!

Nơi nhận/Recipients:

- Như trên/As stated above;
- HĐQT, Ban GD, Ban KS/
Board of Directors, Executive Board,
Supervisory Board,;
- Lưu TC-HC, TCKT.
To be archived by: Administration & Human
Resources Dept, Finance & Accounting Dept

TM. HỘI ĐỒNG QUẢN TRỊ
CHỦ TỊCH
ON BEHALF OF
BOARD OF DIRECTORS
CHAIRMAN



CHỦ TỊCH HĐQT
NGUYỄN TRUNG VIỆT



Số/No.: 06 /Ttr – HĐQT

TỜ TRÌNH/ PROPOSAL

Phương án phát hành cổ phiếu để tăng vốn cổ phần từ nguồn vốn chủ sở hữu năm 2026/Plan for Issuing Shares to Increase Charter Capital from Owner's Equity in 2026

Kính gửi: Đại hội đồng cổ đông Công ty Cổ phần Dược Vật tư Y tế Hải Dương

To the attention of: The General Meeting of Shareholders of Hai Duong

Pharmaceutical and Medical Materials JSC

Căn cứ/ Pursuant to:

- Luật Doanh nghiệp số 59/2020/QH14 ngày 17/6/2020 đã được Quốc hội Nước Cộng Hòa Xã hội Chủ Nghĩa Việt Nam thông qua, sửa đổi bởi Luật số 03/2022/QH15 được Quốc hội thông qua ngày 11/01/2022 và Luật số 76/2025/QH15 được Quốc hội thông qua ngày 17/06/2025 và các văn bản hướng dẫn thi hành;

The Law on Enterprises No. 59/2020/QH14 dated June 17, 2020, passed by the National Assembly of the Socialist Republic of Vietnam, amended by Law No. 03/2022/QH15, passed by the National Assembly of the Socialist Republic of Vietnam on January 11, 2022, and Law No. 76/2025/QH15, passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2025, and its implementing guidance documents;

- Luật Chứng khoán số 54/2019/QH14 ngày 26/11/2019 đã được Quốc hội Nước Cộng Hòa Xã hội Chủ Nghĩa Việt Nam thông qua, sửa đổi bởi Luật số 56/2024/QH15 được Quốc hội nước Cộng hòa Xã hội Chủ nghĩa Việt Nam thông qua ngày 29/11/2024 và các văn bản hướng dẫn thi hành;

The Law on Securities No. 54/2019/QH14 dated November 26, 2019, passed by the National Assembly of the Socialist Republic of Vietnam, amended by Law No. 56/2024/QH15, passed by the National Assembly of the Socialist Republic of Vietnam on November 29, 2024, and its implementing guidance documents;

- Nghị định số 155/2020/NĐ-CP được Chính phủ thông qua ngày 31/12/2020, được sửa đổi bổ sung bởi Nghị định số 245/2025/NĐ-CP ngày 11/09/2025;

Decree No. 155/2020/ND-CP dated December 31, 2020, issued by the Government, amended and supplemented by Decree No. 245/2025/ND-CP dated September 11, 2025;

- Thông tư số 118/2020/TT-BTC ngày 31/12/2020 của Bộ Tài Chính hướng dẫn một số nội dung về chào bán, phát hành chứng khoán, chào mua công khai, mua lại cổ phiếu, đăng ký công ty đại chúng và hủy tư cách công ty đại chúng, được sửa đổi bổ sung bởi Thông tư số 115/2025/TT-BTC ngày 15/12/2025;

Circular No. 118/2020/TT-BTC dated December 31, 2020, issued by the Ministry of Finance guiding certain aspects of securities offering, issuance, public tender offers, share repurchase, public company registration, and public company status cancellation, amended and supplemented by Circular No. 115/2025/TT-BTC dated December 15, 2025;

- Điều lệ tổ chức và hoạt động của Công ty Cổ phần Dược Vật tư Y tế Hải Dương;

The Charter on the organization and operation of Hai Duong Pharmaceutical and Medical Materials JSC;

- Báo cáo tài chính năm 2025 đã được kiểm toán của Công ty cổ phần Dược Vật tư Y tế Hải Dương.

The audited financial statements of Hai Duong Pharmaceutical and Medical Materials JSC for the year 2025.

Hội đồng quản trị kính trình Đại hội đồng cổ đông Công ty Cổ phần Dược Vật tư Y tế Hải Dương xem xét và phê duyệt Phương án phát hành cổ phiếu để tăng vốn cổ phần từ nguồn vốn chủ sở hữu năm 2026 với nội dung chi tiết như sau:

The Board of Directors respectfully submits to the General Meeting of Shareholders of Hai Duong Pharmaceutical and Medical Materials JSC for consideration and approval of the Plan for Issuing Shares to Increase Charter Capital from Owner's Equity in 2026, with the following detailed content:

I. Phương án phát hành cổ phiếu để tăng vốn cổ phần từ nguồn vốn chủ sở hữu năm 2026/ Plan for Issuing Shares to Increase Charter Capital from Owner's Equity in 2026

1. Tổ chức phát hành <i>Issuing organization</i>	Công ty Cổ phần Dược Vật tư Y tế Hải Dương. <i>Hai Duong Pharmaceutical Medical Materials JSC.</i>
2. Loại cổ phiếu <i>Type of shares</i>	Cổ phiếu phổ thông. <i>Common shares.</i>
3. Số lượng phát hành <i>Number of shares to be issued</i>	12.598.575 cổ phần (Mười hai triệu, năm trăm chín mươi tám nghìn, năm trăm bảy mươi lăm cổ phần). <i>12,598,575 shares (Twelve million, five hundred ninety-eight thousand, five hundred seventy-five shares).</i>
4. Tổng giá trị phát hành <i>Total issuance value</i>	125.985.750.000 đồng (Một trăm hai mươi lăm tỷ, chín trăm tám mươi lăm triệu, bảy trăm năm mươi nghìn đồng). <i>125,985,750,000 VND (One hundred twenty-five billion, nine hundred eighty-five million, seven hundred fifty thousand dong).</i>
5. Mệnh giá <i>Par Value</i>	10.000 đồng/cổ phiếu. <i>10,000 VND/share.</i>
6. Mục đích phát hành <i>Purpose of issuance</i>	Tăng vốn điều lệ công ty bằng hình thức phát hành cổ phiếu để tăng vốn cổ phần từ nguồn vốn chủ sở hữu. <i>To increase the company's charter capital by issuing shares to raise share capital from owner's equity.</i>
7. Nguồn vốn phát hành <i>Source of Issuance Capital</i>	Nguồn quỹ đầu tư phát triển và lợi nhuận sau thuế chưa phân phối tại thời điểm 31/12/2025 trên Báo cáo tài chính năm 2025 đã được kiểm toán của Công ty Cổ phần Dược vật tư y tế Hải Dương. Trong đó: - Quỹ đầu tư phát triển: 79.594.214.888 đồng - Lợi nhuận sau thuế chưa phân phối: Tối đa 46.391.535.112 đồng. <i>The issuance capital will be sourced from the Development Investment Fund and Undistributed After-Tax Profit as of December 31st, 2025, according to the audited financial statements of Hai Duong Pharmaceutical and Medical Materials JSC.</i> <i>Details:</i> - <i>Development Investment Fund: 79,594,214,888 VND</i> - <i>Undistributed After-Tax Profit: Up to 46,391,535,112 VND.</i>

<p>8. Đối tượng phát hành <i>Issuance Recipients</i></p>	<p>Cổ đông hiện hữu theo danh sách cổ đông tại ngày đăng ký cuối cùng được hưởng quyền nhận cổ phiếu phát hành từ nguồn vốn chủ sở hữu do VSDC thông báo. <i>Existing shareholders listed on the record date for entitlement to shares issued from owner's equity, as announced by VSDC.</i></p>
<p>9. Tỷ lệ thực hiện <i>Ratio</i></p>	<p>100:35 (Người sở hữu 100 cổ phiếu được nhận 35 cổ phiếu mới). <i>100:35 (Shareholders owning 100 shares will receive 35 new shares).</i></p>
<p>10. Phương án xử lý cổ phiếu lẻ phát sinh (nếu có) <i>Plan for Handling Fractional Shares (if any)</i></p>	<p>Số lượng cổ phiếu mỗi Cổ đông được nhận khi phát hành cổ phiếu để tăng vốn cổ phần từ nguồn vốn chủ sở hữu sẽ được làm tròn đến hàng đơn vị theo nguyên tắc làm tròn xuống. Số cổ phiếu lẻ (phần thập phân) (nếu có) sẽ hủy bỏ, không phát hành. Ví dụ: Cổ đông Nguyễn Văn A sở hữu 175 cổ phiếu, cổ đông A sẽ được nhận cổ phiếu phát hành thêm được tính như sau $(175 : 100) \times 35 = 61,25$ cổ phiếu. Cổ đông Nguyễn Văn A nhận được 61 cổ phiếu mới (cổ phiếu lẻ 0,25 sẽ bị hủy). <i>The number of shares each shareholder receives from the issuance of shares to increase charter capital from owner's equity will be rounded down to the nearest whole number. Any fractional shares (decimal portions), if any, will be canceled and not issued.</i> <i>Example: Shareholder Nguyen Van A owns 175 shares. The additional shares received will be calculated as follows: $(175 : 100) \times 35 = 61.25$ shares. Shareholder Nguyen Van A will receive 61 new shares, and the fractional 0.25 shares will be canceled.</i></p>
<p>11. Thời gian thực hiện dự kiến <i>Expected Implementation Timeline</i></p>	<p>Quý II, III/2026 sau khi được Đại hội đồng cổ đông thông qua và Ủy ban Chứng khoán Nhà nước thông báo bằng văn bản về việc nhận đầy đủ tài liệu báo cáo phát hành của DHD. <i>Quarter II-III/2026, after approval by the General Meeting of Shareholders and upon written confirmation from the State Securities Commission regarding the receipt of the complete issuance report documents from HDPHARMA.</i></p>

II. Điều chỉnh thông tin số lượng chứng khoán đăng ký và đăng ký giao dịch bổ sung/ *Adjustment for number of securities registered information and additional shares trading registration*

Toàn bộ số cổ phiếu phát hành để tăng vốn cổ phần từ nguồn vốn chủ sở hữu năm 2026 sẽ được điều chỉnh thông tin số lượng chứng khoán đăng ký tại Tổng Công ty Lưu ký và Bù trừ chứng khoán Việt Nam và đăng ký giao dịch bổ sung tại Sở Giao dịch Chứng khoán Hà Nội, ngay sau khi hoàn tất việc phát hành phù hợp với quy định pháp luật.

All shares issued to increase charter capital from owner's equity in 2026 will be adjusted for number of securities registered information at the Vietnam Securities Depository and Clearing Corporation and registered for additional shares trading at the Hanoi Stock Exchange immediately after the issuance is completed, in accordance with applicable legal regulations.

III. Sửa đổi điều lệ/ Amendment to the Charter

Sửa đổi các nội dung liên quan đến vốn điều lệ, cổ phần, cổ phiếu tại Mục 1 Phụ lục 1 trong Điều lệ tổ chức và hoạt động của công ty cập nhật theo Vốn điều lệ sau khi hoàn tất đợt phát hành cổ phiếu.

The relevant provisions on charter capital, shares, and stocks is going to be amended in Section 1, Appendix 1 of the company's Charter on organization and operation, updated to reflect the new charter capital after the completion of the share issuance.

IV. Ủy quyền của Đại hội đồng cổ đông cho Hội đồng quản trị/Authorization from the General Meeting of Shareholders to the Board of Directors:

- Triển khai phương án phát hành chi tiết, lựa chọn thời điểm phát hành và thực hiện các thủ tục đăng ký phát hành đảm bảo tuân thủ quy định của pháp luật.

Implement the detailed issuance plan, select the appropriate issuance timing, and carry out the necessary registration procedures in compliance with legal regulations.

- Sửa đổi các nội dung liên quan đến vốn điều lệ, cổ phần, cổ phiếu tại Mục 1 Phụ lục 1 trong Điều lệ tổ chức và hoạt động của công ty cập nhật theo Vốn điều lệ sau khi hoàn tất đợt phát hành cổ phiếu.

Amend the relevant provisions on charter capital, shares, and stocks in Section 1, Appendix 1 of the company's Charter on organization and operation, updated to reflect the new charter capital after the completion of the share issuance.

- Thực hiện các thủ tục pháp lý liên quan sau khi hoàn thành việc phát hành: đăng ký thay đổi nội dung Đăng ký doanh nghiệp đến Cơ quan đăng ký kinh doanh.
Complete the necessary legal procedures upon completion of the issuance, including registering amendments to the business registration details with the Business Registration Authority.
- Hoàn tất thủ tục điều chỉnh thông tin số lượng chứng khoán đăng ký tại Tổng Công ty Lưu ký và Bù trừ Chứng Khoán Việt Nam và đăng ký giao dịch chứng khoán bổ sung trên Sở giao dịch Chứng khoán Hà Nội theo quy định pháp luật hiện hành.
Complete the adjustment for number of securities registered information procedures with the Vietnam Securities Depository and Clearing Corporation and additional shares trading registration on the Hanoi Stock Exchange in accordance with current legal regulations.
- Và các công việc khác có liên quan.
Carry out any other related tasks as necessary.

Kính trình Đại hội xem xét thông qua.

Respectfully submitted to the General Meeting for consideration and approval.

Xin trân trọng cảm ơn!

Sincerely!

TM. HỘI ĐỒNG QUẢN TRỊ
CHỦ TỊCH
ON BEHALF OF
BOARD OF DIRECTORS
CHAIRMAN



CHỦ TỊCH HĐQT
NGUYỄN TRUNG VIỆT

C.P. *
UNG



No.: 07/Ttr – HÐQT

PROPOSAL NO. 07

Re: Amendment and Supplementation of the Company's Business Lines

To: The General Meeting of Shareholders of Hai Duong Pharmaceutical Medical Materials Joint Stock Company

- Pursuant to the Law on Enterprises No. 59/2020/QH14 dated June 17, 2020;
- Pursuant to the Charter of Hai Duong Pharmaceutical Medical Materials Joint Stock Company;
- Pursuant to Decision No. 36/2025/QĐ-TTg dated 29 September 2025 of the Prime Minister promulgating the Vietnam Standard Industrial Classification.

The Board of Directors respectfully submits to the General Meeting of Shareholders for consideration and approval the proposal on the amendment and supplementation of the Company's business lines, with the details as follows:

I. Withdrawal of the following business line(s):

1. Retail sale of other goods via mobile stalls or at markets (Business line code: 4789);
2. Retail sale via mail order or via the Internet (Business line code: 4791);
3. Other retail sale not in stores, stalls or markets and not elsewhere classified (Business line code: 4799);
4. Repair of communication equipment (Business line code: 9512).

Reason for the withdrawal of the business lines:

Decision No. 36/2025/QĐ-TTg dated 29 September 2025 of the Prime Minister promulgating the Vietnam Standard Industrial Classification, which replaces Decision No. 27/2018/QĐ-TTg dated 06 July 2018, has abolished these economic sector codes.

II. Adjustment and supplementation of the following business lines:

No	Business line name prior to amendment	Amended business line name	Reason
1.	<p>Business line code: 0119 Growing of other annual crops Details: Growing of annual spice and aromatic crops.</p>	<p>Business line code: 0119 Growing of other annual crops Details: - Growing of annual spice crops; - Growing of annual medicinal and aromatic plants.</p>	<p>Revision of business line details in accordance with Decision No. 36/2025/QĐ-TTg.</p>
2.	<p>Business line code: 1103 Manufacture of beer and malt.</p>	<p>Business line code: 1103 Manufacture of beer</p>	<p>Change of business line name</p>
3.	<p>Business line code: 1104 Manufacture of non-alcoholic beverages and mineral water</p>	<p>Business line code: 1105 Manufacture of non-alcoholic beverages and mineral water.</p>	<p>Change of business line code</p>
4.		<p>Business line code: 1104 Manufacture of malt.</p>	<p>Addition of business lines.</p>
5.	<p>Business line code: 2023 Manufacture of cosmetics, soap and detergents, cleaning and polishing preparations, and toilet preparations.</p>	<p>Business line code: 2023 Manufacture of cosmetics, perfumes, soap and detergents, cleaning and polishing preparations, and toilet preparations.</p>	<p>Change of business line name</p>

No	Business line name prior to amendment	Amended business line name	Reason
6.	<p>Business line code: 3250</p> <p>Manufacture of medical, dental, orthopedic and rehabilitation instruments and supplies.</p> <p>Details: Manufacture of medical supplies and medical equipment.</p>	<p>Business line code: 3250</p> <p>Manufacture of medical, dental, orthopedic and rehabilitation instruments and supplies.</p> <p>Details:</p> <ul style="list-style-type: none"> - Manufacture of medical and dental instruments and equipment; - Manufacture of orthopedic and rehabilitation devices. 	<p>Change in the detailed scope of the business line</p>
7.	<p>Business line code: 4633</p> <p>Wholesale of beverages</p> <p>Details: Wholesale of wine, beer and soft drinks.</p>	<p>Business line code: 4633</p> <p>Wholesale of beverages</p> <p>Details:</p> <ul style="list-style-type: none"> - Wholesale of alcoholic beverages; - Wholesale of non-alcoholic beverages. 	<p>Change in the detailed scope of the business line</p>
8.	<p>Business line code: 4669</p> <p>Wholesale of other specialized products not elsewhere classified</p> <p>Details:</p> <p>Wholesale of other chemicals (excluding those used in agriculture): chemicals used for the manufacture of pharmaceuticals, cosmetics, health supplements; chemicals used for testing and laboratory purposes;</p>	<p>Business line code: 4679</p> <p>Wholesale of other specialized products not elsewhere classified</p> <p>Details:</p> <p>Wholesale of other chemicals (excluding those used in agriculture), including chemicals used for the manufacture of pharmaceuticals, cosmetics, and health supplements; chemicals for laboratory testing; and chemicals for</p>	<p>Change of business line code</p>

No	Business line name prior to amendment	Amended business line name	Reason
	chemicals used in hospitals; Wholesale of essential oils, medicinal herbs, and eyeglasses.	hospital use; Wholesale of essential oils, medicinal herbs, and eyeglasses.	
9.	Business line code: 4721 Retail sale of food grains in specialized stores Details: Retail sale of rice and maize in specialized stores.	Business line code: 4721 Retail sale of food grains.	Change of business line name
10.	Business line code: 4722 Retail sale of food in specialized stores Details: Retail sale of health supplements.	Business line code: 4722 Retail sale of food.	Change of business line name
11.	Business line code: 4723 Retail sale of beverages in specialized stores Details: Retail sale of beverages, including wine, beer, and non-alcoholic drinks.	Business line code: 4723 Retail sale of beverages	Change of business line name
12.	Business line code: 4724 Retail sale of tobacco products in specialized stores Details: Retail sale of domestically manufactured cigarettes.	Business line code: 4724 Retail sale of tobacco products.	Change of business line name
13.	Business line code: 4741 Retail sale of computers, peripheral equipment, software and telecommunications equipment in specialized stores.	Business line code: 4740 Retail sale of information and communication technology equipment.	Change of business line name; consolidation of two business line with the same product

No	Business line name prior to amendment	Amended business line name	Reason
	Business line code: 4742 Retail sale of audio and video equipment in specialized stores.		group.
14.	Business line code: 4759 Retail sale of electrical household appliances, beds, wardrobes, tables, chairs and similar furniture, lighting equipment and other household articles not elsewhere classified in specialized stores Details: <ul style="list-style-type: none"> - Retail sale of electrical household appliances, lamps and lighting equipment; - Retail sale of beds, wardrobes, tables, chairs and similar furniture; - Retail sale of household articles made of ceramic, porcelain and glass. 	Business line code: 4759 Retail sale of electrical household appliances, beds, wardrobes, tables, chairs and similar furniture, lighting equipment, and other household articles not elsewhere classified Details: <ul style="list-style-type: none"> - Retail sale of electrical household appliances, lamps and lighting equipment; - Retail sale of beds, wardrobes, tables, chairs and similar furniture; - Retail sale of household articles made of ceramic, porcelain and glass. 	Change of business line name
15.	Business line code: 4764 Retail sale of games and toys in specialized stores Details: Retail sale of games and toys made from all types of materials (excluding toys that are harmful to children's moral	Business line code: 4763 Retail sale of games and toys	Change of business line code; change of business line name

No	Business line name prior to amendment	Amended business line name	Reason
	education and health, or that negatively affect security, public order, and social safety).		
16.	<p>Business line code: 4772</p> <p>Retail sale of pharmaceuticals, medical devices, cosmetics and hygiene products in specialized stores.</p>	<p>Business line code: 4772</p> <p>Retail sale of pharmaceuticals, medical devices, cosmetics and hygiene products.</p>	Change of business line name
17.	<p>Business line code: 4773</p> <p>Bán lẻ hàng hóa khác mới trong các cửa hàng chuyên doanh</p> <p>Chi tiết: Bán lẻ tinh dầu, dược liệu, máy móc - thiết bị y tế, hóa chất dùng cho sản xuất thuốc, mỹ phẩm, thực phẩm bảo vệ sức khỏe, phục vụ công tác kiểm nghiệm, hóa chất hàng cho bệnh viện; bán lẻ đồng hồ, kính mắt trong các cửa hàng chuyên doanh</p>	<p>Business line code: 4773</p> <p>Retail sale of other new goods in specialized stores</p> <p>Details: Retail sale of essential oils, medicinal herbs, medical machinery and equipment; chemicals used for the manufacture of pharmaceuticals, cosmetics and health supplements; chemicals used for testing and laboratory purposes and for hospital use; retail sale of watches and eyeglasses in specialized stores.</p>	Change of business line name
18.		<p>Business line code: 5510</p> <p>Hotels and similar accommodation.</p>	Addition of business lines
19.	<p>Business line code: 5510</p> <p>Short-term accommodation services</p>	<p>Business line code: 5520</p> <p>Other short-term accommodation services</p>	Change of business line name

No	Business line name prior to amendment	Amended business line name	Reason
	Details: <ul style="list-style-type: none"> - Villas or apartments providing short-term accommodation services; - Guesthouses or lodging houses providing short-term accommodation services. 	Details: <ul style="list-style-type: none"> - Villas or apartments providing short-term accommodation services; - Guesthouses and lodging houses providing short-term accommodation services. 	
20.	Business line code: 6312 Web portals Details: Establishment of a general information portal.	Business line code: 6310 Information technology infrastructure, data processing, hosting and related activities Details: Establishment of a general information portal.	Change of business line code; change of business line name
21.	Business line code: 6810 Real estate business, including ownership, use rights or leasing of land Details: Leasing of houses for offices, business premises, stores, warehouses, residential houses, and yards.	Business line code: 6810 Real estate business, including ownership, use rights or leasing of land Details: <ul style="list-style-type: none"> - Leasing and operation of residential houses and residential land; - Leasing and operation of non-residential houses and land. 	Change in the detailed scope of the business line code.
22.	Business line code: 7490 Other professional, scientific and technical activities not elsewhere	Business line code: 7499 Other professional, scientific and technical activities not elsewhere classified	Change of business line code

No	Business line name prior to amendment	Amended business line name	Reason
	<p>classified</p> <p>Details: Technical and scientific consultancy services and technology transfer in the fields of pharmaceuticals, cosmetics and food; quality testing services for pharmaceuticals and health supplements.</p>	<p>Details:</p> <ul style="list-style-type: none"> - Scientific and technical consultancy services and technology transfer in the fields of medicine, pharmaceuticals, cosmetics, and food; - Quality testing services for pharmaceuticals and health supplements. 	
23.	<p>Business line code: 7730</p> <p>Renting and leasing of other machinery, equipment and tangible goods</p> <p>Details:</p> <ul style="list-style-type: none"> - Leasing of machinery and equipment used in the medical sector; - Leasing of medical machinery and equipment without an operator. 	<p>Business line code: 7730</p> <p>Renting and leasing of other machinery, equipment and tangible goods without an operator</p> <p>Details: Leasing of machinery and equipment used in the medical sector without an operator.</p>	Change of business line name
24.	<p>Business line code: 7830</p> <p>Human resources supply and management</p> <p>Details: Supply and management of domestic labor resources (excluding labor leasing).</p>	<p>Business line code: 7822</p> <p>Other human resources supply</p> <p>Details: Supply and management of domestic labor resources (excluding labor leasing).</p>	Change of business line code; change of business line name.

No	Business line name prior to amendment	Amended business line name	Reason
25.	<p>Business line code: 9511</p> <p>Repair of computers and peripheral equipment</p> <p>Details: Warranty and repair services for information technology equipment (excluding mechanical processing, waste recycling, and electroplating at the company's premises).</p>	<p>Business line code: 9510</p> <p>Repair and maintenance of computers, information and communication equipment.</p>	<p>Change of business line code; change of business line name.</p>
26.	<p>Business line code: 9639</p> <p>Other personal service activities not elsewhere classified</p> <p>Details: Beauty care services, including:</p> <ul style="list-style-type: none"> - Facial massage; - Manicure and pedicure, makeup, hair removal, etc. 	<p>Business line code: 9622</p> <p>Beauty care services and other beauty treatment activities</p> <p>Details:</p> <ul style="list-style-type: none"> - Facial massage; - Manicure and pedicure, makeup, hair removal, etc. 	<p>Change of business line code; change of business line name; change in the detailed scope of the business line code.</p>

The Board of Directors respectfully submits to the General Meeting of Shareholders for approval and authorizes the Board of Directors to organize the implementation of the above-mentioned contents.

Respectfully submitted to the Annual General Meeting of Shareholders for consideration and approval!

Thank you very much!

**ON BEHALF OF
BOARD OF DIRECTORS
CHAIRMAN**



**CHỦ TỊCH HĐQT
NGUYỄN TRUNG VIỆT**



No.: 08/Ttr – HÐQT

PROPOSAL NO. 08

Re: Amendment to the Charter of Organization and Operation of the Company

To: The General Meeting of Shareholders of Hai Duong Pharmaceutical Medical Materials Joint Stock Company

- Pursuant The Law on Enterprises No. 59/2020/QH14 dated June 17, 2020, passed by the National Assembly of the Socialist Republic of Vietnam, amended by Law No. 03/2022/QH15, passed by the National Assembly of the Socialist Republic of Vietnam on January 11, 2022, and Law No. 76/2025/QH15, passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2025, and its implementing guidance documents ;
- Pursuant to the Charter of Hai Duong Pharmaceutical Medical Materials Joint Stock Company;
- Pursuant to Decision No. 36/2025/QĐ-TTg dated 29 September 2025 of the Prime Minister promulgating the Vietnam Standard Industrial Classification.

Based on the review of the Company Charter, the Board of Directors has identified that certain provisions in the Charter need to be considered for amendment and supplementation to better align with current practices. Therefore, the Board of Directors respectfully submits to the General Meeting of Shareholders the proposal to amend and supplement the Charter of Organization and Operation of Hai Duong Pharmaceutical Medical Materials Joint Stock Company as follows:

Provisions stipulated in the current Company Charter	Proposed amendments	Reason for amendments
Article 2. Name, legal form, head office, branches, representative offices, and duration of operation of the Company	Article 2. Name, legal form, head office, branches, representative offices, and duration of operation of the Company.	Amend to reflect actual circumstances.
3. The registered head office of the Company is:	3. The registered head office of the Company is:	
- Address: No. 102 Chi Lang Street, Nguyen Trai Ward, Hai	- Address: No. 102 Chi Lang	



Provisions stipulated in the current Company Charter	Proposed amendments	Reason for amendments
<p>Duong City, Hai Duong Province.</p> <p>4. The Company has two legal representatives: the Chairman of the Board of Directors and the General Director.</p> <p>5. The Company may establish branches and representative offices in business locations to carry out its operational objectives, in accordance with the decisions of the Board of Directors and within the scope permitted by law.</p> <p>The Company has five branches within Hai Duong Province; one branch in Hanoi, one branch in Ho Chi Minh City, one branch in the Central Region, and one branch in Can Tho.</p> <ul style="list-style-type: none"> - Five branches within the province are located in districts of Hai Duong Province. - Hanoi Branch: Lot 01-D6C, Vuon Dao Villa Area, Xuan La Ward, Tay Ho District, Hanoi. - Ho Chi Minh City Branch: No. 99, 101-TML Street, Thanh My Loi Ward, Thu Duc City, Ho Chi Minh City. - Central Region Branch: Lot 9-C4, Hoa Phat 4 Residential Area, Hoa An Ward, Cam Le 	<p>Street, Thanh Dong Ward, Hai Phong City.</p> <p>4. The Company has one legal representative, who is the General Director.</p> <p>5. The Company may establish branches and representative offices both domestically and overseas to carry out its operational objectives, in accordance with the decisions of the Board of Directors and within the scope permitted by law.</p>	

ST
 HO
 SP
 OV
 Y T
 AI D
 ONG

Provisions stipulated in the current Company Charter	Proposed amendments	Reason for amendments
<p>District, Da Nang City.</p> <ul style="list-style-type: none"> - Can Tho Branch: L09-53-54, Street No. 7, Stella Residential Area, Binh Thuy Ward, Binh Thuy District, Can Tho City. 		
<p>Article 3. Business lines and operational objectives of the Company</p> <p>1. The Company's business lines include: ... (Detailed business lines and corresponding business line codes are specified.)</p>	<p>1. The Company's business lines: The Company conducts business in accordance with the business lines stated in the Enterprise Registration Certificate and in compliance with applicable laws.</p>	<p>For the convenience of the Company's operations, in the event of any changes to the business lines, amendment of the Company Charter shall not be required.</p>

Respectfully submitted to the Annual General Meeting of Shareholders for consideration and approval!

Thank you very much!

**ON BEHALF OF
BOARD OF DIRECTORS
CHAIRMAN**



**CHỦ TỊCH HĐQT
NGUYỄN TRUNG VIỆT**



Số: 09/Ttr – HĐQT
No: 09/TTr – HĐQT

TỜ TRÌNH SỐ 09
PROPOSAL NO. 09

Về việc thông qua các hợp đồng, giao dịch giữa
Công ty Cổ phần Dược Vật tư Y tế Hải Dương với người có liên quan
*Regarding the approval of contracts and transactions between
Hai Duong Pharmaceutical Medical Equipment Joint Stock Company
and related parties*

Kính gửi: Đại hội đồng cổ đông Công ty Cổ phần Dược Vật tư y tế Hải Dương
**To: The General Meeting of Shareholders of Hai Duong Pharmaceutical
Medical Equipment Joint Stock Company**

- Luật Doanh nghiệp số 59/2020/QH14 ngày 17/6/2020 đã được Quốc hội Nước Cộng Hòa Xã hội Chủ Nghĩa Việt Nam thông qua, sửa đổi bởi Luật số 03/2022/QH15 được Quốc hội thông qua ngày 11/01/2022 và Luật số 76/2025/QH15 được Quốc hội thông qua ngày 17/06/2025 và các văn bản hướng dẫn thi hành;

The Law on Enterprises No. 59/2020/QH14 dated June 17, 2020, passed by the National Assembly of the Socialist Republic of Vietnam, amended by Law No. 03/2022/QH15, passed by the National Assembly of the Socialist Republic of Vietnam on January 11, 2022, and Law No. 76/2025/QH15, passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2025, and its implementing guidance documents;

- Luật Chứng khoán số 54/2019/QH14 ngày 26/11/2019 đã được Quốc hội Nước Cộng Hòa Xã hội Chủ Nghĩa Việt Nam thông qua, sửa đổi bởi Luật số 56/2024/QH15 được Quốc hội nước Cộng hòa Xã hội Chủ nghĩa Việt Nam thông qua ngày 29/11/2024 và các văn bản hướng dẫn thi hành;

The Law on Securities No. 54/2019/QH14 dated November 26, 2019, passed by the National Assembly of the Socialist Republic of Vietnam, amended by Law No. 56/2024/QH15, passed by the National Assembly of the Socialist Republic of Vietnam on November 29, 2024, and its implementing guidance documents;



- Căn cứ Nghị định 155/2020/NĐ-CP quy định chi tiết thi hành Luật Chứng khoán;
Pursuant to Decree No. 155/2020/ND-CP detailing the implementation of the Securities Law;
- Căn cứ Điều lệ tổ chức và hoạt động Công ty Cổ phần Dược Vật tư Y tế Hải Dương ("DHD")
Pursuant to the Charter of Organization and Operation of Hai Duong Pharmaceutical Medical Equipment Joint Stock Company ("DHD").

Hội đồng quản trị kính trình Đại hội đồng cổ đông xem xét thông qua các hợp đồng, giao dịch giữa Công ty với người có liên quan như sau:
The Board of Directors respectfully submits to the General Meeting of Shareholders for approval the contracts and transactions between the Company and related parties as follows:

1. Phê duyệt các hợp đồng và giao dịch với Công ty TNHH Dược VTYT Hải Dương hoặc đơn vị hạch toán phụ thuộc được Công ty TNHH Dược VTYT Hải Dương uỷ quyền (nếu có); có giá trị từ 10% hoặc các giao dịch dẫn đến tổng giá trị giao dịch phát sinh trong vòng 12 tháng kể từ ngày thực hiện giao dịch đầu tiên trong năm 2026, có giá trị từ 10% trở lên tổng giá trị tài sản của Công ty ghi trong báo cáo tài chính công bố tại thời điểm gần nhất đối với:

Approval of contracts and transactions with Hai Duong Pharmaceutical Medical Equipment Co., Ltd or its dependent accounting units authorized by Hai Duong Pharmaceutical Medical Equipment Co., Ltd (if any), with a value of 10% or more, or transactions leading to a total transaction value arising within 12 months from the date of the first transaction in 2026, amounting to 10% or more of the Company's total asset value recorded in the latest published financial statements, for the following services:

- Dịch vụ Bán buôn, bán lẻ thuốc, dụng cụ y tế, mỹ phẩm, thực phẩm bảo vệ sức khỏe;

Wholesale and retail services of pharmaceuticals, medical instruments, cosmetics, and health supplements;

- Dịch vụ bán buôn bán lẻ hóa chất;

Wholesale and retail services of chemicals;

- Dịch vụ cho thuê máy móc, thiết bị y tế;





ĐẠI HỘI ĐỒNG CỔ ĐÔNG THƯỜNG NIÊN NĂM 2026
ANNUAL GENERAL MEETING OF SHAREHOLDERS 2026

Rental services for medical machinery and equipment;

- Dịch vụ Đại lý mua bán thuốc chữa bệnh, hoá mỹ phẩm, thực phẩm bảo vệ sức khỏe, dụng cụ y tế, thiết bị y tế, kính mắt, dược liệu, tinh dầu, hóa chất và vật phẩm vệ sinh

Agency services for the purchase and sale of pharmaceuticals, cosmetics, health supplements, medical instruments, medical equipment, eyewear, medicinal herbs, essential oils, chemicals, and hygiene products;

- Dịch vụ Bán lẻ theo yêu cầu đặt hàng qua bưu điện hoặc internet.

Retail services based on orders placed via mail or the internet.

2. Thời gian thực hiện: Từ ngày Nghị quyết của Đại hội đồng cổ đông thông qua các nội dung nêu trên có hiệu lực cho đến Đại hội đồng cổ đông thường niên năm 2027.

Implementation period: From the date the General Meeting of Shareholders' resolution approving the above contents takes effect until the 2026 Annual General Meeting of Shareholders.

3. Đại hội đồng cổ đông thường niên năm 2026 Ủy quyền cho Hội đồng Quản trị và cho phép Hội đồng Quản trị giao cho Ban Giám đốc Công ty quyết định các điều khoản, cũng như giao kết thực hiện từng hợp đồng, giao dịch cụ thể căn cứ theo tình hình thực tế của Công ty và tiến hành các thủ tục liên quan đến việc ký kết và thực hiện các hợp đồng, giao dịch nêu trên.

Authorization: The 2026 Annual General Meeting of Shareholders authorizes the Board of Directors and allows the Board of Directors to delegate the Company's Executive Board to determine the terms and execute specific contracts and transactions based on the Company's actual situation, as well as carry out necessary procedures related to the signing and execution of the aforementioned contracts and transactions.

Kính trình Đại hội đồng cổ đông xem xét thông qua./.

We respectfully submit this for the General Meeting of Shareholders' review and approval.

Xin trân trọng cảm ơn!

Sincerely,

**TM. HỘI ĐỒNG QUẢN TRỊ
CHỦ TỊCH
ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRMAN**



**CHỦ TỊCH HĐQT
NGUYỄN TRUNG VIỆT**

